学术周报 · IF≥10

神经内科领域文献阅读汇编

2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
62
临床研究
24
基础研究
38
IF≥20
18
IF 10-20
44
子领域
20
期刊种类
37
数据日期
2026-10-31

★本周 Top 10 高影响力文献

#论文期刊IF
1Spatiotemporally resolved single-nucleus transcriptomics reveals cellular and regional vulnerability...Signal transduction and targeted therapyIF 81.2
2Alzheimer's disease genetics converges on microglial and neuronal dysregulation.NatureIF 56.1
3Persistent and compartmentalized T cell immunity in ALS.Nature medicineIF 52.5
4Safety of low lipoprotein(a) levels: the FOURIER trial.European heart journalIF 45.3
5Guardians at the gate: cMAF keeps the brain's vasculature in check.CellIF 45.1
6Brain perivascular macrophages regulate endothelial cell function via a cMAF-dependent transcription...CellIF 45.1
7A Female-Specific Life Course Approach to the Prevention and Management of Cardiovascular Disease: A...CirculationIF 41.3
8Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A Sc...CirculationIF 41.3
9Initial fixed low-versus moderate-dose hydroxyurea assignment in the long-term follow-up of the SPRI...BloodIF 23.9
10Changing Patterns of Transient Ischemic Attack Evaluation in US Emergency Departments.JAMA neurologyIF 23.6

Ŧ期刊分布统计

期刊篇数IF
Stroke7IF 11.1
Ageing research reviews3IF 15.5
Neuron3IF 16.9
Pharmacological research3IF 12.2
European journal of preventive cardiology3IF 10.0
JAMA neurology3IF 23.6
Molecular psychiatry2IF 10.4
Science advances2IF 13.9
Acta pharmacologica Sinica2IF 10.4
Advanced healthcare materials2IF 11.0

1脑血管病与卒中 (20篇)

临床研究 (11篇)

Stroke IF 11.1 2026-10-30 PMID: 42961033
Patients with medium or distal vessel occlusion stroke are heterogeneous. Randomized trials show no net benefit of endovascular treatment (EVT) over best medical treatment (BMT) alone, which may mask heterogeneity of treatment effect. We used an externally developed machine learning model to predict excellent early neurological outcome (EENO) with BMT alone and examined whether the effect of EVT differed across predicted risk. A Tabular Prior-Data Fitted Network (TabPFN) model was trained to predict EENO (24-hour National Institutes of Health Stroke Scale [NIHSS] score of 0-2) in patients with medium or distal vessel occlusion treated with BMT alone in a local Bernese Stroke Registry. This model was applied to patients from the DISTAL randomized trial (55 centers and 11 countries), who were randomized to EVT plus BMT or BMT alone. We tested for interaction between predicted EENO and treatment allocation on the primary outcome (90-day modified Rankin Scale shift), repeating this using admission NIHSS alone. In the development cohort (n=257, 42% female, and mean age 70.4±14.8 years), 54% achieved EENO. In the DISTAL cohort (270 BMT alone, 269 EVT plus BMT, 44% female, and mean age 74.9±12.0 years), the model showed moderate external discrimination (area under the receiver operating characteristic curve 0.73). A significant interaction was found between predicted EENO and treatment effect (Pinteraction=0.012): in 152 patients predicted to achieve EENO, EVT was associated with worse 90-day modified Rankin Scale score (common odds ratio, 0.48 [95% CI, 0.27-0.84]), whereas no treatment effect was seen in 387 patients predicted not to achieve EENO (common odds ratio 1.13 [95% CI, 0.79-1.60]). A model using admission NIHSS alone showed comparable discrimination (area under the receiver operating characteristic curve 0.71) and a common odds ratio for EVT of 0.47 (95% CI, 0.25-0.89) in patients with an NIHSS score of ≤4 and a common odds ratio of 1.05 (95% CI, 0.75-1.47) in patients with an NIHSS score of >4 (Pinteraction=0.029). EVT was harmful in patients with medium or distal vessel occlusion predicted to achieve EENO with BMT alone, and an NIHSS-alone model performed comparably to the multivariable model. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05029414.
中文摘要:中等或远端血管闭塞卒中患者具有异质性。随机试验显示血管内治疗(EVT)较单纯最佳药物治疗(BMT)无净获益,这可能掩盖治疗效应异质性。研究使用外部开发的机器学习模型预测单纯BMT下的早期神经功能优良结局(EENO),并检验EVT效应是否随预测风险不同而变化。研究在伯尔尼卒中登记中训练表格先验数据拟合网络(TabPFN)模型,用于预测接受单纯BMT的中等或远端血管闭塞患者的EENO(24小时美国国立卫生研究院卒中量表NIHSS评分0~2分),并将该模型应用于DISTAL随机试验(55个中心、11个国家)中随机接受EVT联合BMT或单纯BMT的患者。研究检验预测EENO与治疗分配对主要结局(90天改良Rankin量表评分偏移)的交互作用,并使用入院NIHSS单独重复该分析。开发队列257例,女性42%,平均年龄70.4±14.8岁,54%达到EENO。DISTAL队列中单纯BMT 270例,EVT联合BMT 269例,女性44%,平均年龄74.9±12.0岁;模型显示中等外部区分度(受试者工作特征曲线下面积0.73)。预测EENO与治疗效应之间存在显著交互作用(交互作用P=0.012):在152例预测可达到EENO的患者中,EVT与更差的90天改良Rankin量表评分相关(共同比值比0.48[95% CI 0.27~0.84]),而在387例预测不能达到EENO的患者中未见治疗效应(共同比值比1.13[95% CI 0.79~1.60])。仅使用入院NIHSS的模型显示相近区分度(受试者工作特征曲线下面积0.71);NIHSS评分≤4分的患者中EVT的共同比值比为0.47(95% CI 0.25~0.89),NIHSS评分>4分的患者中为1.05(95% CI 0.75~1.47)(交互作用P=0.029)。在预测单纯BMT即可达到EENO的中等或远端血管闭塞患者中,EVT有害;仅用NIHSS的模型与多变量模型表现相近。注册网址:https://www.clinicaltrials.gov;唯一标识:NCT05029414。
Stroke IF 11.1 2026-10-30 PMID: 42960430
The ABCD2 score is widely used to stratify stroke risk after transient neurological events. We aimed to evaluate the association between the ABCD2 score and the risk of subsequent ischemic stroke among patients with diffusion-weighted imaging (DWI)-positive (DWI+) or DWI-negative (DWI-) findings for the index event. We pooled individual participant data from 3 multicenter cohorts including patients presenting with transient or minor neurological events. Patients presenting with transient neurological symptoms, a normal neurological examination, and available DWI for the index event were included. Associations between the ABCD2 score and 90-day ischemic stroke risk were analyzed separately in the DWI+ and DWI- groups using logistic regression models adjusted for sex, atrial fibrillation, and study source. Among 2014 patients (1143 [56.8%] men; median age 67 years), the median ABCD2 score was 4 (interquartile range, 3-5), and 504 (25.0%) were DWI+. Ischemic stroke occurred within 90 days in 20 patients (4.0%) in the DWI+ group and 33 (2.2%) in the DWI- group. The ABCD2 score was associated with stroke risk in the DWI- group (per 1-point increase, odds ratio, 1.36 [95% CI, 1.04-1.79]), but this relationship was not significant in the DWI+ group (per 1-point increase, odds ratio, 1.08 [95% CI, 0.76-1.53]). When stratified ABCD2 score into 0 to 3, 4 to 5, and 6 to 7, the predicted 90-day stroke risks were 3.2%, 3.9%, and 4.5% in the DWI+ group (per 1-category increase, odds ratio, 1.23 [95% CI, 0.63-2.40]) and 1.0%, 2.3%, and 4.1% in the DWI- group (per 1-category increase, odds ratio, 1.88 [95% CI, 1.11-3.20]), respectively. The ABCD2 score was associated with 90-day stroke risk among patients with DWI- findings. Patients with both a low ABCD2 score and DWI- findings had a particularly low risk of subsequent stroke, which may inform risk stratification and clinical decision-making after transient neurological events.
中文摘要:ABCD2评分常用于对短暂性神经系统事件后的卒中风险进行分层。本研究评估在索引事件弥散加权成像阳性(DWI+)或阴性(DWI-)的患者中,ABCD2评分与后续缺血性卒中风险的关系。汇总3个多中心队列的个体参与者数据,纳入表现为短暂性或轻微神经系统事件的患者。纳入标准为短暂性神经系统症状、神经系统查体正常且索引事件有可用DWI。分别在DWI+组和DWI-组中,采用校正性别、心房颤动和研究来源的logistic回归模型分析ABCD2评分与90天缺血性卒中风险的关联。2014例患者中(1143例男性,56.8%;中位年龄67岁),ABCD2评分中位数为4(四分位间距3-5),504例(25.0%)为DWI+。90天内缺血性卒中在DWI+组发生20例(4.0%),在DWI-组发生33例(2.2%)。ABCD2评分与DWI-组的卒中风险相关(每增加1分,比值比1.36,95%置信区间1.04-1.79),但在DWI+组中该关系不显著(每增加1分,比值比1.08,95%置信区间0.76-1.53)。将ABCD2评分分为0-3、4-5和6-7分层后,DWI+组预测的90天卒中风险分别为3.2%、3.9%和4.5%(每增加1个类别,比值比1.23,95%置信区间0.63-2.40),DWI-组分别为1.0%、2.3%和4.1%(每增加1个类别,比值比1.88,95%置信区间1.11-3.20)。ABCD2评分与DWI-患者的90天卒中风险相关。ABCD2评分低且DWI-的患者后续卒中风险尤其低,这可能有助于短暂性神经系统事件后的风险分层和临床决策。
European journal of preventive cardiology IF 10.0 2026-10-29 PMID: 42954724
To characterize the pattern of chronotropic incompetence (CI) response to exercise in patients with heart failure (HF) across distinct phenotypes of the left ventricular ejection fraction and to explore the extent to which heart rate (HR) response should be prioritized as a therapeutic target within personalized HF management strategies. Patients with HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), and healthy controls underwent incremental exercise testing with simultaneous gas exchange and echocardiography assessments. Stroke volume (SV), HR, cardiac output (CO), and arteriovenous oxygen difference [C(a-v)O2] were assessed from rest to peak exercise. Graphical analyses explored relationships amongst determinants of oxygen uptake (V̇O2). Both HF phenotypes exhibited CI and a blunted increase in CO during exercise compared with controls. Peak HR was similarly reduced by 20% in HFpEF and 23% in HFrEF. HFpEF, however, exhibited a steeper HR-VO2 relationship. HFrEF demonstrated a greater compensatory increase in peripheral O2 extraction, with peak C(a-v)O2 73% higher than controls and 21% higher than HFpEF. In contrast, HFpEF showed limited ability to augment C(a-v)O2 and presented the lowest relative peak V̇O2 (-39% vs. controls and -16% vs. HFrEF), despite similar peak V̇O2%pred between HF phenotypes. CI can contribute to exercise intolerance in both HF phenotypes, with distinct compensatory mechanisms. An integrated cardiopulmonary exercise testing-echocardiography approach may support identifying phenotype-specific physiological profiles that might address therapeutic strategies targeting CI, SV reserve, and peripheral O2 utilization to improve functional capacity in HF. Addressing the kinetics of HR slope and ΔHR metrics seems relevant to implement knowledge on the fundamental CI contribution in HF phenotypes.
中文摘要:本研究刻画不同左室射血分数表型心力衰竭患者运动时变时功能不全(CI)的表现模式,并探讨在个体化心衰管理中把心率反应作为治疗靶点的优先程度。射血分数保留的心衰(HFpEF)、射血分数降低的心衰(HFrEF)患者与健康对照接受递增负荷运动试验,同步进行气体交换与超声心动图评估,从静息至峰值运动测定每搏量、心率、心输出量及动静脉氧差。用图示分析探讨摄氧量各决定因素之间的关系。两种心衰表型均存在变时功能不全,运动时心输出量增加亦较对照钝化;峰值心率在HFpEF降低约20%,在HFrEF降低约23%。HFpEF的心率-摄氧量关系更陡。HFrEF外周氧摄取代偿性增加更明显,峰值动静脉氧差较对照高73%,较HFpEF高21%。HFpEF提升动静脉氧差的能力有限,相对峰值摄氧量最低(较对照低39%,较HFrEF低16%),而两种表型的峰值摄氧量占预计值百分比相近。变时功能不全可导致两种心衰表型的运动不耐受,但代偿机制不同。整合心肺运动试验与超声心动图的方法有助于识别表型特异的生理特征,从而针对变时功能不全、每搏量储备与外周氧利用制定治疗策略,改善心衰患者的功能容量。厘清心率斜率动力学与心率变化指标的规律,似有助于加深对变时功能不全在心衰各表型中基础作用的认识。
Stroke IF 11.1 2026-10-29 PMID: 42953960
Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy. This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days. Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35-3.21]; P=0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29-2.44]; P=0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05-2.77]; P=0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34-1.22]; P=0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group. Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05624190.
中文摘要:近期多项试验显示,机械取栓成功再通后联合动脉内溶栓在获得优良预后方面可能有获益,但结果并不一致。本研究按取栓后扩大脑梗死溶栓评分(eTICI)对患者分层,考察动脉内溶栓的疗效与安全性。本分析为ANGEL-TNK试验(急性大血管闭塞机械取栓成功再通后动脉内重组人TNK-tPA溶栓;多中心、随机、开放标签、盲法终点)的预设二次分析。纳入前循环大血管闭塞患者,在eTICI 2b50至3级再灌注后按1:1随机接受动脉内替奈普酶(TNK,0.125 mg/kg)或标准内科治疗。主要结局为90天改良Rankin量表评分0至1分的比例。安全性结局包括48小时内症状性颅内出血与任何颅内出血,以及90天内死亡。253例入组患者中,164例为eTICI 2b50至67组,89例为eTICI 2c至3组。血管内治疗(EVT)后动脉内TNK与eTICI 2b50至67患者90天改良Rankin量表评分0至1分比例更高相关(39例[44.8%]对15例[19.5%];相对危险度2.08[95% CI,1.35-3.21];P=0.001),在eTICI 2c至3患者中未见此种关联(12例[30.8%]对19例[38.0%];相对危险度0.84[95% CI,0.29-2.44];P=0.749)。eTICI 2c至3组中,动脉内TNK使48小时内任何颅内出血增加(13例[33.3%]对10例[20.0%];相对危险度1.70[95% CI,1.05-2.77];P=0.032),eTICI 2b50至67组无此现象(18例[20.7%]对25例[32.5%];相对危险度0.65[95% CI,0.34-1.22];P=0.176)。两组的48小时内症状性颅内出血与90天内死亡均无差异。EVT后动脉内TNK可为eTICI 2b50至67患者带来90天改良Rankin量表评分0至1分的优良预后获益,对eTICI 2c至3患者则无此获益;在该组中动脉内TNK增加任何颅内出血风险,但未升高症状性颅内出血或死亡风险。注册网址:https://www.clinicaltrials.gov;唯一标识:NCT05624190。
Stroke IF 11.1 2026-10-29 PMID: 42953941
Patients with atrial fibrillation (AF) and prior ischemic stroke represent a high-risk population facing competing risks of recurrent thromboembolism and hemorrhagic complications. Although direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists for stroke prevention in AF, no randomized controlled clinical trial has directly compared individual DOACs to each other in this population. We conducted a systematic review and frequentist random-effects network meta-analysis of randomized-controlled clinical trials enrolling patients with AF and prior ischemic stroke or transient ischemic attack. MEDLINE, Scopus, and ClinicalTrials.gov were searched from inception until May 2026. The primary outcome was any stroke. Secondary outcomes included ischemic stroke, hemorrhagic stroke, major bleeding, intracranial hemorrhage (ICH), cardiovascular mortality, and all-cause mortality. Treatment effects were expressed as risk ratios (RR) with 95% CIs. The evidence network comprised 6 trials (18 395 patients) in a star-shaped structure. Each DOAC was informed by a single warfarin-controlled trial, and 2 trials used aspirin as the comparator. All between-DOAC comparisons were indirect. In the network meta-analysis, compared with warfarin, apixaban was the only agent to significantly reduce both any stroke (RR, 0.72 [95% CI, 0.53-0.97]) and major bleeding (RR, 0.73 [95% CI, 0.54-0.99]). Dabigatran, apixaban, and edoxaban each significantly reduced hemorrhagic stroke and ICH versus warfarin, whereas rivaroxaban did not reach significance for any bleeding outcome. Edoxaban was the only agent associated with significantly lower cardiovascular (RR, 0.79 [95% CI, 0.65-0.97]) and all-cause mortality (RR, 0.84 [95% CI, 0.72-0.99]). Based on indirect comparisons only, no differences between individual DOACs were observed. In patients with AF and prior ischemic stroke, individual DOACs reduced intracranial and systemic bleeding relative to warfarin, although not uniformly across agents. Apixaban alone significantly reduced both any stroke and major bleeding versus warfarin, but differences between individual DOACs could not be established given the small number of trials. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261404062.
中文摘要:合并心房颤动与既往缺血性卒中的患者属于高危人群,同时面临血栓栓塞复发与出血并发症的竞争风险。直接口服抗凝药(DOAC)在房颤卒中预防中优于维生素K拮抗剂,但尚无随机对照临床试验在该人群中直接比较不同DOAC。研究对纳入房颤合并既往缺血性卒中或短暂性脑缺血发作患者的随机对照临床试验进行系统评价和频率学随机效应网络荟萃分析。检索MEDLINE、Scopus和ClinicalTrials.gov,时间自建库至2026年5月。主要结局为任何卒中。次要结局包括缺血性卒中、出血性卒中、重大出血、颅内出血(ICH)、心血管死亡和全因死亡。治疗效果以风险比(RR)及95%CI表示。证据网络包含6项试验、18 395例患者,呈星形结构。每种DOAC均由单一华法林对照试验提供证据,2项试验以阿司匹林为对照。所有DOAC之间的比较均为间接比较。网络荟萃分析中,与华法林相比,阿哌沙班是唯一同时显著降低任何卒中(RR 0.72,95%CI 0.53-0.97)和重大出血(RR 0.73,95%CI 0.54-0.99)的药物。达比加群、阿哌沙班和艾多沙班均显著降低出血性卒中和ICH风险,利伐沙班在任何出血结局上均未达到显著性。艾多沙班是唯一与心血管死亡(RR 0.79,95%CI 0.65-0.97)和全因死亡(RR 0.84,95%CI 0.72-0.99)显著降低相关的药物。仅基于间接比较,未观察到不同DOAC之间的差异。在房颤合并既往缺血性卒中患者中,各DOAC相对华法林可减少颅内和系统性出血,但并非所有药物一致。阿哌沙班是唯一相对华法林同时显著降低任何卒中和重大出血的药物,但鉴于试验数量较少,尚不能确定不同DOAC之间的差异。URL:https://www.crd.york.ac.uk/PROSPERO/;唯一标识:CRD420261404062。
Stroke IF 11.1 2026-10-29 PMID: 42953937
Patients with atrial fibrillation who experience ischemic stroke despite oral anticoagulation (breakthrough stroke) remain at high risk of recurrent vascular events and death. Although inflammation has been associated with thromboembolic risk, its prognostic role in breakthrough stroke remains unclear. We investigated whether a composite inflammatory burden index was associated with adverse outcomes after breakthrough ischemic stroke. We conducted a multicenter retrospective cohort study of consecutive patients with breakthrough ischemic stroke from the ASPERA-R registry. Inflammatory burden was assessed using admission neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and C-reactive protein. Biomarkers were log-transformed, standardized using Z scores, and combined into a composite inflammatory burden index. Patients were classified as having high (upper tertile) or lower inflammatory burden (lower 2 tertiles). Outcomes included new 90-day ischemic events (recurrent ischemic stroke, transient ischemic attack, or systemic embolism), 24-hour hemorrhagic transformation, and 90-day moderate-to-severe bleeding, intracranial hemorrhage, and mortality. Inverse probability of treatment weighting accounted for center, demographics, vascular risk factors and comorbidities, anticoagulation, competing stroke causes, baseline National Institutes of Health Stroke Scale, prestroke modified Rankin Scale, and time to blood collection. Among 1649 patients enrolled in ASPERA-R, 671 patients from 14 centers had complete biomarker data (median age, 80.1 years [interquartile range, 73.5-85.5]; 52.3% female). Of these, 223 (33.2%) had high inflammatory burden, and 448 (66.8%) had lower inflammatory burden. After weighting, high inflammatory burden was associated with increased risks of ischemic events at 90 days (hazard ratio, 1.53 [95% CI, 1.02-2.30]), all-cause mortality (hazard ratio, 1.70 [95% CI, 1.17-2.47]), moderate-to-severe bleeding (hazard ratio, 2.92 [95% CI, 1.04-8.17]), and hemorrhagic transformation at 24 hours (odds ratio, 2.18 [95% CI, 1.43-3.33]). In breakthrough ischemic stroke, high inflammatory burden was associated with increased risks of recurrent ischemic events, mortality, hemorrhagic transformation, and major bleeding. A composite of routinely available inflammatory biomarkers may help identify patients with higher residual vascular risk.
中文摘要:在接受口服抗凝治疗情况下仍发生缺血性卒中的心房颤动患者(突破性卒中)仍有较高的复发性血管事件和死亡风险。炎症与血栓栓塞风险相关,但其在突破性卒中中的预后作用尚不清楚。研究探讨复合炎症负荷指数是否与突破性缺血性卒中后的不良结局相关。研究为多中心回顾性队列研究,连续纳入ASPERA-R登记中的突破性缺血性卒中患者。炎症负荷采用入院时中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、系统性免疫炎症指数和C反应蛋白评估。生物标志物经对数转换并以Z评分标准化后合并为复合炎症负荷指数。患者分为高炎症负荷组(上三分位)和较低炎症负荷组(下两个三分位)。结局包括90天内新发缺血事件(复发性缺血性卒中、短暂性脑缺血发作或系统性栓塞)、24小时出血转化,以及90天中重度出血、颅内出血和死亡。逆概率治疗加权校正了中心、人口学特征、血管危险因素和合并症、抗凝治疗、竞争性卒中病因、基线美国国立卫生研究院卒中量表评分、卒中前改良Rankin量表评分和采血时间。ASPERA-R登记的1649例患者中,14个中心共671例具有完整生物标志物数据(中位年龄80.1岁[四分位距73.5-85.5];女性52.3%)。其中223例(33.2%)为高炎症负荷,448例(66.8%)为较低炎症负荷。加权后,高炎症负荷与90天缺血事件风险增加相关(风险比1.53[95%置信区间1.02-2.30])、全因死亡风险增加相关(风险比1.70[95%置信区间1.17-2.47])、中重度出血风险增加相关(风险比2.92[95%置信区间1.04-8.17]),并与24小时出血转化风险增加相关(比值比2.18[95%置信区间1.43-3.33])。在突破性缺血性卒中中,高炎症负荷与复发性缺血事件、死亡、出血转化和大出血风险增加相关。由常规可获得的炎症生物标志物构成的复合指标可能有助于识别残余血管风险较高的患者。
Stroke IF 11.1 2026-10-29 PMID: 42953922
The aim of this study was to investigate the association between PAR-1 (protease-activated receptor-1) gene F2R polymorphisms and the efficacy of clopidogrel therapy initiated within a time window extended to 72 hours for mild ischemic stroke or transient ischemic attack with intracranial or extracranial atherosclerosis. This was a secondary analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), a randomized clinical trial conducted at 222 centers across China between September 2018 and October 2022. Four single-nucleotide polymorphisms (F2R [IVSn-14 A/T, rs168753], CYP2C19*2 [681G>A, rs4244285], CYP2C19*3 [636G>A, rs4986893], and CYP2C19*17 [-806C>T, rs12248560]) were genotyped among 5791 patients treated with clopidogrel plus aspirin (n=2894) or aspirin alone (n=2897). The primary efficacy outcome was new stroke, and the safety outcome was moderate-to-severe bleeding within 90 days. Cox proportional hazards models were used to estimate the interaction between treatment assignment and F2R polymorphisms for the primary outcomes. Among 5791 patients, 1698 (29.3%) were AA homozygotes, and 4093 (70.7%) were the T-allele carriers (AT/TT) for F2R IVSn-14 polymorphisms. Compared with aspirin alone, clopidogrel-aspirin reduced the rate of new stroke in patients with AT/TT genotype (7.1% versus 9.2%; hazard ratio [HR], 0.77 [95% CI, 0.62-0.95]; P=0.02) but not in carriers of the AA genotype (7.7% versus 8.1%; HR, 0.95 [95% CI, 0.67-1.33]; P=0.75; P=0.30 for interaction). For the safety outcome, the risk of moderate-to-severe bleeding between the clopidogrel plus aspirin group and aspirin group was not significant in patients with AT/TT genotype (HR, 1.91 [95% CI, 0.85-4.29]; P=0.12) or AA genotype (HR, 1.97 [95% CI, 0.59-6.55]; P=0.27; P=0.97 for interaction). Moreover, the presence of CYP2C19 loss-of-function allele carrier status did not alter the effect of the F2R polymorphisms on clinical outcomes, although a marginally reduced risk of stroke with clopidogrel-aspirin versus aspirin alone was observed only among carriers of at least 1 F2R IVSn-14 T allele without CYP2C19 loss-of-function allele (HR, 0.73 [95% CI, 0.52-1.01]; P=0.06). With the treatment initiated within a time window extended to 72 hours after mild ischemic stroke or transient ischemic attack onset, we found that clopidogrel plus aspirin may reduce the occurrence of new stroke specifically in F2R IVSn-14 T-allele carriers. This finding suggests that the clopidogrel-aspirin treatment may appear more beneficial among carriers of the F2R IVSn-14 T allele. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.
中文摘要:该研究旨在探讨PAR-1(蛋白酶激活受体-1)基因F2R多态性与轻症缺血性卒中或伴颅内或颅外动脉粥样硬化的短暂性脑缺血发作患者,在延长至72小时的时间窗内启动氯吡格雷治疗的疗效之间的关系。该研究为INSPIRES试验(急性高危颅内或颅外动脉粥样硬化的强化他汀与抗血小板治疗)的二次分析,该随机临床试验于2018年9月至2022年10月在中国222家中心开展。对5791例接受氯吡格雷联合阿司匹林(n=2894)或单用阿司匹林(n=2897)治疗的患者进行了四个单核苷酸多态性(F2R [IVSn-14 A/T, rs168753]、CYP2C19*2 [681G>A, rs4244285]、CYP2C19*3 [636G>A, rs4986893]和CYP2C19*17 [-806C>T, rs12248560])的基因分型。主要疗效结局为新发卒中,安全性结局为90天内中重度出血。采用Cox比例风险模型估计治疗分组与F2R多态性对主要结局的交互作用。在5791例患者中,F2R IVSn-14多态性AA纯合子1698例(29.3%),T等位基因携带者(AT/TT)4093例(70.7%)。与单用阿司匹林相比,氯吡格雷联合阿司匹林降低了AT/TT基因型患者的新发卒中发生率(7.1%对9.2%;风险比[HR] 0.77 [95% CI 0.62-0.95];P=0.02),但在AA基因型携带者中未见降低(7.7%对8.1%;HR 0.95 [95% CI 0.67-1.33];P=0.75;交互作用P=0.30)。安全性结局方面,AT/TT基因型(HR 1.91 [95% CI 0.85-4.29];P=0.12)或AA基因型(HR 1.97 [95% CI 0.59-6.55];P=0.27;交互作用P=0.97)患者中,氯吡格雷联合阿司匹林组与阿司匹林组的中重度出血风险均无显著差异。此外,CYP2C19功能缺失等位基因携带状态并未改变F2R多态性对临床结局的影响,尽管仅在携带至少1个F2R IVSn-14 T等位基因且不携带CYP2C19功能缺失等位基因的患者中观察到氯吡格雷联合阿司匹林较单用阿司匹林有边缘性降低的卒中风险(HR 0.73 [95% CI 0.52-1.01];P=0.06)。在轻症缺血性卒中或短暂性脑缺血发作发病后延长至72小时的时间窗内启动治疗的情况下,研究发现氯吡格雷联合阿司匹林可能仅在F2R IVSn-14 T等位基因携带者中减少新发卒中的发生。这一结果提示,氯吡格雷联合阿司匹林治疗在F2R IVSn-14 T等位基因携带者中可能更有获益。URL: https://www.clinicaltrials.gov;唯一标识符:NCT03635749。
European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 40795405
Chronic opioid exposure (COE) is linked to adverse health outcomes, but its relationship with cardiovascular disease (CVD) remains unclear. This systematic review and meta-analysis aimed to summarize published evidence on CVD risk associated with COE, including prescription opioids, opium use, and opioid use disorder (OUD). Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and International Prospective Register of Systematic Reviews registration (CRD42024573206), we searched multiple databases for relevant human studies reporting associations between COE and CVD. Random-effects meta-analysis estimated pooled odds ratios (ORs) with 95% confidence intervals. Subgroup analyses and meta-regression explored associations by COE type, CVD outcome, and potential moderators. Risk of bias was assessed using Risk Of Bias In Non-randomized Studies - of Exposures. Seventeen studies (1 676 000 participants) met inclusion criteria, with 13 studies contributing 22 effect sizes to meta-analysis. Chronic opioid exposure was associated with increased CVD risk (pooled OR, 1.74; 95% CI, 1.12-2.70), though substantial heterogeneity was observed. Cerebrovascular accidents (OR, 1.84; 95% CI, 1.45-2.35) and ischaemic heart disease (OR, 1.51; 95% CI, 1.40-1.63) showed the strongest associations. Opium use had a significant association with CVD, whilst findings for OUD and prescription opioids were less consistent. Meta-regression identified study design as a key moderator. Chronic opioid exposure is associated with increased risk of CVD, particularly cerebrovascular accidents and ischaemic heart disease. Given the global opioid and CVD burden, targeted interventions and integrated care approaches are needed. Findings are limited by heterogeneity and risk of bias in published studies. Further high-quality research should explore pathophysiological mechanisms, causality, dose-response relationships, and the potential reversibility of CVD risk following opioid cessation.
中文摘要:慢性阿片暴露(COE)与不良健康结局相关,但其与心血管疾病(CVD)的关系仍不明确。本系统评价和荟萃分析旨在汇总已发表证据,评估COE相关CVD风险,涵盖处方阿片类药物、鸦片使用和阿片类药物使用障碍(OUD)。研究遵循PRISMA指南和国际前瞻性系统评价注册(CRD42024573206),检索多个数据库,纳入报告COE与CVD关联的人体研究。采用随机效应荟萃分析估计汇总比值比(OR)及95%置信区间,并通过亚组分析和荟萃回归探讨COE类型、CVD结局及潜在调节因素。偏倚风险采用非随机暴露研究偏倚风险工具评估。共17项研究(1 676 000名参与者)符合纳入标准,其中13项研究提供22个效应量进入荟萃分析。COE与CVD风险升高相关(汇总OR 1.74;95%CI 1.12-2.70),但异质性较大。脑血管意外(OR 1.84;95%CI 1.45-2.35)和缺血性心脏病(OR 1.51;95%CI 1.40-1.63)关联最强。鸦片使用与CVD存在显著关联,OUD和处方阿片类药物的结果一致性较低。荟萃回归识别研究设计为关键调节因素。COE与CVD风险升高相关,尤其是脑血管意外和缺血性心脏病。鉴于全球阿片类药物和CVD负担,需要针对性干预和整合照护策略。已发表研究的异质性和偏倚风险限制了结论。后续高质量研究应探索病理生理机制、因果关系、剂量反应关系以及停用阿片类药物后CVD风险的可逆性。
Blood IF 23.9 2026-10-26 PMID: 42932254
In this pragmatic long-term follow-up of the SPRINT randomized trial cohort, rates of recurrent stroke and all-cause mortality did not differ significantly by an initial fixed low- versus moderate-dose of hydroxyurea over 4.9 years, with events clustering in the first year.
中文摘要:在SPRINT随机试验队列的实用性长期随访中,初始固定低剂量与中等剂量羟基脲治疗在4.9年内的复发性卒中率和全因死亡率无显著差异,事件集中在第一年。
JAMA neurology IF 23.6 2026-10-26 PMID: 42931749
For US patients presenting to the emergency department (ED) with transient ischemic attack (TIA), guidelines recommend resource-intensive multimodal evaluation to optimize secondary stroke prevention. These resources are not available in all EDs, and national patterns of ED TIA care are not well described. To evaluate national trends in ED TIA care, including discharge practices, imaging use, and associated costs, and to assess patient- and hospital-level factors associated with these patterns. This was a retrospective repeated cross-sectional study of ED visits using the 2013-2021 National Emergency Department Sample of the Healthcare Cost and Utilization Project, a weighted, nationally representative annual sample of ED visits in the US. TIA and stroke encounters during the study period were identified among patients aged 18 years or older by a first-listed International Classification of Diseases, Ninth Revision or Tenth Revision code for TIA or stroke diagnosis. Analyses were performed from October 2024 to April 2026. Calendar year. ED discharge; imaging use among discharged TIA encounters; and inflation-adjusted ED cost per discharged encounter. This study included 2 151 408 (95% CI, 2 107 855-2 194 960) weighted ED visits for TIA (1 194 630 [55.5%] female; mean [SEM] age, 69.8 [0.05] years). Adjusted models found the predicted probability of discharge increased from 45% (95% CI, 43%-46%) in 2013 to 66% (95% CI, 64%-68%) in 2021 (P < .001 for trend). During this time, mean ED charges increased from $1746 (95% CI, $1662-$1830) to $2755 (95% CI, $2674-$2836) per encounter (P < .001 for trend). Imaging use among discharged TIA encounters increased substantially, including computed tomography angiography (predicted probability, 4% [95% CI, 3%-4%] in 2013 vs 45% [95% CI, 42%-47%] in 2021; P < .001 for trend) and magnetic resonance imaging (predicted probability, 17% [95% CI, 16%-19%] in 2013 vs 53% [95% CI, 50%-55%] in 2021; P < .001 for trend). Rate of discharge was higher in rural encounters than in urban encounters for all years studied, and the rate of magnetic resonance imaging use was lower. This cross-sectional study demonstrates a shift in TIA care over time that suggests increased use of the ED to expedite evaluation for TIA that previously occurred during a brief hospitalization. This approach has consequences in terms of cost and ED throughput and may not be as feasible in rural hospitals as it is in urban hospitals.
中文摘要:在美国,因短暂性脑缺血发作(TIA)到急诊科就诊的患者,指南推荐采用资源密集的多模式评估,以优化卒中二级预防。这些资源并非所有急诊科都具备,全国急诊科TIA诊疗模式也缺乏充分描述。本研究评估急诊科TIA诊疗的全国趋势,包括离院情况、影像使用和相关费用,并分析与这些模式相关的患者层面和医院层面因素。研究为回顾性重复横断面研究,使用医疗成本与利用项目2013—2021年全国急诊科样本,该样本为美国急诊就诊的加权、全国代表性年度样本。研究期间,在18岁及以上患者中,以首位ICD-9或ICD-10编码诊断为TIA或卒中的就诊记录被识别。分析时间为2024年10月至2026年4月。暴露变量为日历年。结局包括急诊离院、离院TIA就诊中的影像使用,以及每次离院就诊经通胀调整的急诊费用。研究纳入2 151 408次(95% CI,2 107 855—2 194 960)加权TIA急诊就诊,其中女性1 194 630次(55.5%),平均(SEM)年龄69.8(0.05)岁。校正模型显示,离院预测概率从2013年的45%(95% CI,43%—46%)升至2021年的66%(95% CI,64%—68%)(趋势检验P<.001)。同期,每次就诊平均急诊收费从1746美元(95% CI,1662—1830美元)升至2755美元(95% CI,2674—2836美元)(趋势检验P<.001)。离院TIA就诊的影像使用大幅增加,包括CT血管成像(预测概率2013年4%[95% CI,3%—4%],2021年45%[95% CI,42%—47%];趋势检验P<.001)和磁共振成像(预测概率2013年17%[95% CI,16%—19%],2021年53%[95% CI,50%—55%];趋势检验P<.001)。研究各年份农村就诊的离院率均高于城市就诊,磁共振成像使用率较低。该横断面研究显示TIA诊疗随时间发生转变,提示更多利用急诊科加快TIA评估,而这类评估过去常在短暂住院期间完成。这一方式在费用和急诊周转方面带来后果,在农村医院可能不如城市医院可行。
European heart journal IF 45.3 2026-10-26 PMID: 42234492
Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13-165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02-1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02-1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38-1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
中文摘要:Lp(a)被认为是动脉粥样硬化的因果危险因素。有报道低Lp(a)浓度患者某些不良事件(包括糖尿病)患病率更高。降低Lp(a)的治疗药物已进入临床测试,因此较低Lp(a)浓度与安全性结局之间的关联具有临床意义。FOURIER试验将27 564例稳定动脉粥样硬化性心血管疾病(ASCVD)患者随机分配至依洛尤单抗组或安慰剂组,背景为他汀治疗。研究在校正相关预测因素后分析Lp(a)与关注的现患和新发不良结局风险之间的关系。25 090例参与者评估了基线Lp(a)(中位37 nmol/L,四分位距13-165)。Lp(a)浓度与新发出血性卒中、严重出血、神经认知事件、恶性肿瘤或心房颤动的风险无关,包括Lp(a)≤13 nmol/L者。基线Lp(a)较低与基线时现患糖尿病呈负相关(每降低50 nmol/L,校正比值比1.03,95%CI 1.02-1.04,P<.001),也与随访期间新发糖尿病风险呈负相关(每降低50 nmol/L,校正风险比1.05,95%CI 1.02-1.08,P=.002),按治疗组分析结果一致。无论基线Lp(a)如何,依洛尤单抗均未增加糖尿病风险;即使在基线Lp(a)最高十分位者中(依洛尤单抗使Lp(a)中位降低71 nmol/L),校正HR为0.72(95%CI 0.38-1.35)。在ASCVD患者中,低Lp(a)浓度与大多数不良安全性结局风险增加无关,但较低Lp(a)与现患和新发糖尿病风险增加相关。

基础研究 (9篇)

Acta biomaterialia IF 10.4 2026-10-30 PMID: 42962843
Proper cerebral artery function is essential for maintaining the brain's microenvironment. The multilayered organization of cellular and extracellular matrix (ECM) constituents enables large cerebral arteries to accommodate pulse pressure and ensure both effective blood distribution and protection of the microcirculation. However, aging and disease induce compositional and structural remodeling in cerebral arteries, such as the middle cerebral artery (MCA), which can alter biomechanical properties and increase susceptibility to cerebrovascular conditions including atherosclerosis and aneurysms, both major contributors to stroke. Understanding how age-related changes in arterial structure and composition influence biomechanical behavior is critical for improving prediction of cerebrovascular risk. In this study, we characterized the age-dependent elastic and viscoelastic properties of human MCAs and related these changes to ECM structure and composition using imaging and biochemical assays. Our results demonstrate that aging is associated with increased stiffness and stress relaxation in MCAs. Biochemical analyses revealed age-related increases in collagen and glycosaminoglycan (GAG) content, both of which correlated with altered mechanical properties. Histological staining further showed denser collagen organization within the adventitia and elevated GAG presence, consistent with mechanical and biochemical findings. Additionally, multiphoton imaging under mechanical loading provided insight into layer-specific collagen reorganization in the adventitia. Collectively, these findings elucidate key age-dependent alterations in the structure-function relationship of human cerebral arteries and provide a mechanistic basis for increased cerebrovascular risk with aging. STATEMENT OF SIGNIFICANCE: Age-related remodeling of the extracellular matrix is a fundamental driver of tissue dysfunction, yet its effects on human cerebral artery mechanics remain poorly understood. In this study, we combine biomechanical testing, biochemical assays, histology, and multiphoton microscopy to characterize structural and functional remodeling of human middle cerebral arteries across a broad age range. We demonstrate that aging is associated with increased arterial stiffness and viscoelastic relaxation, accompanied by elevated collagen and glycosaminoglycan content. By directly linking extracellular matrix composition and organization to biomechanical function, this work provides new insights into the mechanisms governing cerebrovascular aging. These findings establish an important structure function framework for understanding vascular tissue remodeling and have broader implications for age related vascular dysfunction, mechanobiology, and biomaterials research.
中文摘要:脑动脉功能正常对于维持脑微环境至关重要。细胞与细胞外基质(ECM)成分的多层组织使大型脑动脉能够承受脉压,并保证有效的血液分布和对微循环的保护。衰老和疾病会诱导脑动脉发生成分与结构重构,例如大脑中动脉(MCA),从而改变生物力学特性并增加对动脉粥样硬化和动脉瘤等脑血管病变的易感性,这两类病变均是卒中的重要原因。理解动脉结构和成分的年龄相关变化如何影响生物力学行为,对于改进脑血管风险预测十分关键。该研究表征了人MCA随年龄变化的弹性和黏弹性特性,并通过成像和生化检测将这些变化与ECM结构和成分联系起来。结果显示,衰老与MCA刚度增加和应力松弛增强相关。生化分析显示胶原和糖胺聚糖(GAG)含量随年龄增加,二者均与力学特性改变相关。组织学染色进一步显示外膜内胶原组织更致密、GAG存在增加,与力学和生化结果一致。机械加载下的多光子成像为了解外膜中分层特异的胶原重组提供了线索。这些发现阐明了人脑动脉结构-功能关系中关键的年龄相关改变,并为衰老相关脑血管风险增加提供了机制基础。意义声明:细胞外基质与年龄相关的重构是组织功能障碍的基本驱动因素,但其对人脑动脉力学的影响仍知之甚少。该工作结合生物力学测试、生化检测、组织学和多光子显微镜,在较宽的年龄范围内表征人大脑中动脉的结构和功能重构。研究显示,衰老与动脉刚度增加和黏弹性松弛增强相关,并伴随胶原和糖胺聚糖含量升高。通过将细胞外基质成分和组织方式直接与生物力学功能联系起来,该工作为理解脑血管衰老机制提供了新认识。这些发现建立了理解血管组织重构的重要结构-功能框架,并对年龄相关血管功能障碍、力学生物学和生物材料研究具有更广泛意义。
Stroke IF 11.1 2026-10-30 PMID: 42960431
Recovery after ischemic stroke is limited by persistent cerebrovascular dysfunction, but the mechanisms regulating vascular repair remain poorly understood. Prnd (Prnd/Doppel) is a prion family protein expressed in the cerebrovascular endothelium during development. We tested the hypothesis that endothelial Prnd promotes vascular repair and functional recovery in the adult brain after stroke. Using middle cerebral artery occlusion in mice, we compared wild-type and Prnd-null mice and evaluated endothelial-specific Prnd overexpression. Functional recovery was assessed by behavioral testing, while infarct volume, brain atrophy, vascular architecture, blood-brain barrier integrity, and macrophage/microglia infiltration were evaluated histologically. Vascular signaling and endothelial cell junctional proteins were examined mechanistically. Acute infarct volumes were comparable between wild-type and Prnd-null mice, indicating that Prnd does not substantially affect initial ischemic injury. During recovery, however, Prnd-null mice exhibited disrupted cerebrovascular architecture, increased blood-brain barrier disruption, greater brain atrophy, and increased macrophage/microglial infiltration. Conversely, endothelial Prnd overexpression improved long-term functional recovery without altering acute infarct size and was associated with enhanced blood-brain barrier integrity and vascular remodeling. Mechanistically, Prnd manipulation was associated with enhanced VEGF-A (vascular endothelial growth factor-A) signaling and increased endothelial cell tight junction protein expression. Prnd is dispensable for acute ischemic injury but promotes cerebrovascular remodeling, blood-brain barrier restoration, and functional recovery after stroke. These findings identify endothelial Prnd as a regulator of poststroke vascular repair and a potential therapeutic target for enhancing long-term recovery.
中文摘要:缺血性卒中后的恢复受持续性脑血管功能障碍限制,但调控血管修复的机制仍不清楚。Prnd(Prnd/Doppel)是一种在发育期脑血管内皮表达的朊蛋白家族蛋白。我们检验了内皮Prnd促进成年脑卒中后血管修复和功能恢复的假说。采用小鼠大脑中动脉闭塞模型,比较野生型与Prnd缺失小鼠,并评估内皮特异性Prnd过表达。功能恢复通过行为学测试评估,梗死体积、脑萎缩、血管结构、血脑屏障完整性和巨噬细胞/小胶质细胞浸润通过组织学评估。机制上检查血管信号和内皮细胞连接蛋白。野生型与Prnd缺失小鼠急性梗死体积相当,提示Prnd对初始缺血损伤无明显影响。恢复期,Prnd缺失小鼠出现脑血管结构破坏、血脑屏障破坏增加、脑萎缩更明显以及巨噬细胞/小胶质细胞浸润增加。相反,内皮Prnd过表达改善长期功能恢复而不改变急性梗死体积,并与血脑屏障完整性和血管重塑增强相关。机制上,Prnd调控与VEGF-A信号增强及内皮细胞紧密连接蛋白表达增加相关。Prnd对急性缺血损伤非必需,但促进卒中后脑血管重塑、血脑屏障恢复和功能恢复。这些发现确定内皮Prnd是卒中后血管修复的调控因子,也是增强长期恢复的潜在治疗靶点。
Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957749
Diabetes mellitus-associated endothelial dysfunction represents a pivotal early event in diabetic vasculopathy, linking metabolic derangements to vascular injury. Dimethyl fumarate (DMF), an FDA-approved drug for multiple sclerosis and psoriasis, exhibits potent anti-inflammatory and antioxidant properties, yet whether it protects against diabetic endothelial dysfunction and the underlying molecular mechanisms remain unclear. Here, diabetic db/db mice and the non-diabetic db/m+ littermates were treated with DMF (100 mg·kg-1·d-1) or vehicle for 4 weeks, and vascular function in aortic and mesenteric artery rings was assessed by wire myography. Human umbilical vein endothelial cells (HUVECs) and endothelial cell (EC)-specific Tfeb knockout (TfebECKO) mice were employed to investigate the target of DMF in vitro and in vivo. DMF restored the impaired endothelium-dependent relaxations (EDRs) in db/db mouse aortas and insulin-induced relaxations in mesenteric arteries, improved glucose tolerance, reduced aortic endothelial mitochondrial ROS (mito-ROS) accumulation, and lowered the expression of inflammatory markers. IL-1β induced phosphorylation and cytoplasmic retention of TFEB (indicative of TFEB inhibition), mito-ROS production, and inflammatory responses in HUVECs and mouse aortas, all of which were reversed by DMF pretreatment. These protective effects of DMF were largely reversed by TFEB knockdown in HUVECs or in aortas of TfebECKO mice. RNA sequencing data analysis revealed a substantial overlap between DMF-regulated and TFEB-overexpression transcriptional profiles, implicating a role of TFEB in DMF-induced suppression of inflammatory and oxidative pathways. Together, DMF ameliorates endothelial dysfunction in diabetes by inhibiting TFEB phosphorylation and restoring TFEB nuclear activity. Endothelial TFEB represents a critical mediator responsible for the vaso-protective effects of DMF and a promising therapeutic target for the treatment of diabetic vascular complications.
中文摘要:糖尿病相关内皮功能障碍是糖尿病血管病变的关键早期事件,将代谢紊乱与血管损伤联系起来。富马酸二甲酯(DMF)已获FDA批准用于多发性硬化和银屑病,具有强效抗炎和抗氧化特性,但其能否改善糖尿病内皮功能障碍及其分子机制仍不清楚。研究对糖尿病db/db小鼠及非糖尿病db/m+同窝对照小鼠给予DMF(100 mg·kg-1·d-1)或溶媒治疗4周,并用金属丝肌张力测定评估主动脉和肠系膜动脉环的血管功能。采用人脐静脉内皮细胞(HUVECs)和内皮细胞特异性Tfeb敲除(TfebECKO)小鼠,在体外和体内研究DMF的作用靶点。DMF恢复了db/db小鼠主动脉受损的内皮依赖性舒张(EDR)和肠系膜动脉的胰岛素诱导舒张,改善了糖耐量,减少了主动脉内皮线粒体ROS(mito-ROS)蓄积,并降低了炎症标志物表达。IL-1β在HUVECs和小鼠主动脉中诱导TFEB磷酸化及胞质滞留(提示TFEB受抑制)、mito-ROS产生和炎症反应,DMF预处理可逆转这些改变。DMF的这些保护作用在HUVECs中敲低TFEB或TfebECKO小鼠主动脉中大部分被逆转。RNA测序数据分析显示,DMF调控的转录谱与TFEB过表达的转录谱存在大量重叠,提示TFEB参与DMF对炎症和氧化通路的抑制。DMF通过抑制TFEB磷酸化并恢复TFEB核活性改善糖尿病内皮功能障碍。内皮TFEB是DMF血管保护作用的关键介导者,也是治疗糖尿病血管并发症的有前景靶点。
Advanced healthcare materials IF 11.0 2026-10-29 PMID: 42958811
Stroke causes substantial reorganization of neural activity and connectivity in the peri-infarct cortex during functional recovery. Tracking these changes at high resolution, however, remains difficult. Mechanical mismatch of conventional rigid neural probes is exacerbated in the fragile peri-infarct region, destabilizing the tissue-electrode interface and limiting long-term recording. Here, we present a fully soft, liquid metal-based multichannel neural interface that enables stable electrophysiological recording in freely moving mice. Using this platform, we performed longitudinal recordings before and after ischemic stroke, enabling within-animal comparisons. We applied complementary analyses of population-level latent dynamics and functional connectivity, capturing network-level coordination and pairwise interactions. Both analyses revealed acute suppression followed by partial recovery without restoration of the pre-stroke state. Instead, neural networks reorganized into a distinct and reproducible functional configuration. These findings establish soft liquid metal neural interfaces combined with population-level analysis as a useful approach for resolving neural reorganization during stroke recovery.
中文摘要:卒中后功能恢复期间,梗死周围皮质的神经活动与连接会发生显著重组,但高分辨率追踪这些变化仍较困难。传统刚性神经探针的机械失配在脆弱的梗死周围区域更为突出,会破坏组织与电极界面的稳定性并限制长期记录。我们提出一种全软液态金属多通道神经接口,可在自由活动小鼠中实现稳定的电生理记录。借助该平台,我们在缺血性卒中前后进行纵向记录,实现同一动物内比较。我们采用群体水平潜在动力学与功能连接的互补分析,捕捉网络层面的协调和成对相互作用。两类分析均显示急性抑制后出现部分恢复,但未恢复至卒中前状态;神经网络转而重组为一种独特且可重复的功能构型。这些结果确立软液态金属神经接口结合群体水平分析,可作为解析卒中恢复期神经重组的有用方法。
Autophagy IF 18.6 2026-10-29 PMID: 42926339
Porcine astrovirus (PAstV) infection predominantly results in diarrhea and encephalitis in suckling piglets, yet the underlying pathogenic mechanisms remain poorly understood. In this study, the PAstV1-GX1 strain, previously isolated, was utilized to infect PK-15 cells. The results demonstrated that PAstV infection induced pronounced endoplasmic reticulum (ER) stress, as evidenced by the upregulation of HSPA5/GRP78 expression, and macroautophagy/autophagy, indicated by the increased conversion of MAP1LC3/LC3 from LC3-I to LC3-II and decreased expression of SQSTM1/p62. Pharmacological mitigation of ER stress effectively suppressed autophagy, suggesting that PAstV facilitates autophagy via ER stress. Further mechanistic investigations identified that PAstV infection selectively activated the EIF2AK3/PERK-EIF2S1/eIF2α-ATF4 pathway within the unfolded protein response, establishing this pathway as the pivotal upstream signal mediating autophagy. Through the screening of viral proteins, the capsid protein was identified as the primary viral component responsible for inducing ER stress and autophagy. This protein was concurrently localized to both mitochondria and the ER, where it interacted with the MAVS (mitochondrial antiviral signaling protein). The capsid protein facilitated the degradation of MAVS via the autophagy pathway and an apoptosis-related pathway in a non-classical, caspase-3-independent manner, thereby suppressing the production of type I interferons. Modulating ER stress, autophagy, or apoptosis greatly impacted the capsid protein's suppression of type I interferons. This suggested that the capsid protein hindered type I interferon production by triggering ER stress, which activated autophagy and possibly apoptosis, resulting in MAVS degradation. These insights lay the groundwork for understanding PAstV's pathogenic mechanisms and aid in developing new antiviral treatments.Abbreviations: 3-MA: 3-methyladenine; 4-PBA: 4-phenylbutyric acid; ACTB/β-actin: actin beta; ATF4: activating transcription factor 4; ATF6: activating transcription factor 6; CCK-8: Cell Counting Kit-8; Co-IP: co-immunoprecipitation; CQ: chloroquine; DAPI: 4,6-diamidino-2-phenylindole; DDIT3/CHOP: DNA damage inducible transcript 3; EGFP: enhanced green fluorescent protein; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; EIF2S1/eIF2α: eukaryotic translation initiation factor 2 subunit alpha; ER: endoplasmic reticulum; ERN1/IRE1: endoplasmic reticulum to nucleus signaling 1; hpi: hours post-infection; HSPA5/GRP78: heat shock protein family A (Hsp70) member 5; IFIT1/ISG56: interferon induced protein with tetratricopeptide repeats 1; IFN: interferon; IFNB1/IFN-β: interferon beta 1; ISG15: ISG15 ubiquitin like modifier; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAVS: mitochondrial antiviral signaling protein; MOI: multiplicity of infection; PBS: phosphate-buffered saline; PAstV: porcine astrovirus; phospho-EIF2S1: phosphorylated EIF2S1; PPP1R15A/GADD34: protein phosphatase 1 regulatory subunit 15A; RAPA: rapamycin; RT-PCR: reverse transcription polymerase chain reaction; RT-qPCR: reverse transcription quantitative polymerase chain reaction; SeV: Sendai virus; siRNA: small interfering RNA; SQSTM1/p62: sequestosome 1; TG: thapsigargin; TU: tunicamycin; UPR: unfolded protein response; UV: ultraviolet; VSV-GFP: vesicular stomatitis virus expressing green fluorescent protein; WCL: whole-cell lysate; XBP1: X-box binding protein 1.
中文摘要:猪星状病毒(PAstV)感染主要导致哺乳仔猪腹泻和脑炎,其致病机制仍不清楚。本研究用先前分离的PAstV1-GX1株感染PK-15细胞。结果显示,PAstV感染引起明显的内质网应激,表现为HSPA5/GRP78表达上调,并诱导巨自噬/自噬,表现为MAP1LC3/LC3由LC3-I向LC3-II转化增加及SQSTM1/p62表达下降。药物缓解内质网应激可有效抑制自噬,提示PAstV经内质网应激促进自噬。进一步机制研究发现,PAstV感染选择性激活未折叠蛋白反应中的EIF2AK3/PERK-EIF2S1/eIF2α-ATF4通路,该通路是介导自噬的关键上游信号。通过筛选病毒蛋白,鉴定出衣壳蛋白是诱导内质网应激和自噬的主要病毒成分。该蛋白同时定位于线粒体和内质网,并与MAVS(线粒体抗病毒信号蛋白)相互作用。衣壳蛋白以非经典、不依赖caspase-3的方式,通过自噬途径和凋亡相关途径促进MAVS降解,从而抑制I型干扰素产生。调控内质网应激、自噬或凋亡会明显影响衣壳蛋白对I型干扰素的抑制作用。这提示衣壳蛋白通过触发内质网应激,激活自噬并可能激活凋亡,导致MAVS降解,进而阻碍I型干扰素产生。这些发现为理解PAstV致病机制奠定基础,并有助于开发新的抗病毒治疗手段。
Nature neuroscience IF 20.3 2026-10-28 PMID: 42951997
Brain myeloid cells, including infiltrating monocyte-derived macrophages (MDMs) and microglia, play critical roles in ischemic brain injury, clearing debris and shaping neuroinflammation and neurological outcomes. Yet the underlying mechanisms remain unclear. Here, using single-cell RNA sequencing and fate mapping with an MDM-specific Ms4a3creERT2-Ai14 mouse line, we identified serotonin receptor Htr2b+ MDMs as a crucial cell population involved in resolving neuroinflammation within the ischemic penumbra. Htr2b+ MDMs significantly accumulate in the peri-infarct region and exhibit enhanced phagocytosis and inflammation-resolving gene signatures. Mechanistically, Htr2b activation promotes nuclear translocation of Tfe3, a key lysosomal regulator, enhancing lysosomal biogenesis and supporting phagocytic activity. MDM-specific Htr2b ablation impairs debris clearance, exacerbates neuroinflammation and ischemic injury, whereas pharmacological agonism or Tfe3 activation restores lysosomal biogenesis in brain MDMs and improves post-stroke outcomes. Thus we demonstrate a previously unrecognized Htr2b+ MDM subset that integrates serotonin signaling to license intrinsic phagocytic function, alleviating ischemic brain injury.
中文摘要:脑髓系细胞,包括浸润性单核细胞来源巨噬细胞(MDMs)和小胶质细胞,在缺血性脑损伤中发挥关键作用,负责清除碎片并塑造神经炎症和神经功能结局。其潜在机制仍不清楚。我们利用单细胞RNA测序和MDM特异性Ms4a3creERT2-Ai14小鼠系的命运图谱,鉴定出5-羟色胺受体Htr2b+ MDMs是参与缺血半暗带内神经炎症消退的关键细胞群体。Htr2b+ MDMs在梗死周围区域显著聚集,并表现出增强的吞噬作用和炎症消退基因特征。机制上,Htr2b激活促进关键溶酶体调节因子Tfe3的核转位,增强溶酶体生物发生并支持吞噬活性。MDM特异性Htr2b缺失损害碎片清除,加重神经炎症和缺血性损伤,而药理学激动或Tfe3激活可恢复脑MDMs中的溶酶体生物发生并改善卒中后结局。我们由此证明了一个此前未被认识的Htr2b+ MDM亚群,其整合5-羟色胺信号以使内在吞噬功能得以发挥,减轻缺血性脑损伤。
Advanced drug delivery reviews IF 21.0 2026-10-26 PMID: 42933662
Nanoparticles (NPs) have emerged as versatile platforms for drug delivery in cardiovascular diseases (CVDs), demonstrating robust efficacy in preclinical models by stabilizing atherosclerotic plaques, promoting safe and efficient thrombolysis, and mitigating ischemia-reperfusion injury. These advances highlight the maturation of cardiovascular nanomedicine; however, translation to clinical practice remains limited. This gap between laboratory success and clinical adoption reflects broader challenges in nanomedicine design, including suboptimal delivery to diseased tissues, limited efficacy of single therapeutic payload-based strategies in addressing the multifaceted inflammatory pathways driving CVDs, NPs' immunogenicity, and scale-up feasibility. Addressing these barriers is particularly critical in CVDs, where therapeutic success depends on precise engagement with multiple molecular and cellular drivers of disease. This review discusses the evolving landscape of cardiovascular nanomedicine, focusing on four aspects. First, we highlight advances in NPs bioengineering strategies, such as refined targeting moieties, optimized physicochemical properties, and responsiveness to endogenous and external stimuli that enhance organ- and cell-specific delivery in atherosclerosis, myocardial infarction, and stroke. Second, we discuss analytical innovations that improve characterization and control of NPs' biodistribution, enabling more rational targeting. Third, we evaluate therapeutic payloads, emphasizing how RNA-based and immunomodulatory agents represent a meaningful step toward clinical translation. Fourth, we outline approaches to addressing persistent challenges in safety and scalable manufacturing. Together, these developments establish a foundation for translating NP design principles into practical cardiovascular therapies. With continued progress in targeted delivery, clinical safety, and production scalability, cardiovascular nanomedicine is increasingly well-positioned to translate preclinical advances to transformative patient outcomes.
中文摘要:纳米颗粒(NPs)已成为心血管疾病(CVDs)药物递送的多功能平台,在临床前模型中显示出稳健疗效,可稳定动脉粥样硬化斑块、促进安全有效的溶栓并减轻缺血-再灌注损伤。这些进展表明心血管纳米医学日趋成熟,但向临床实践的转化仍然有限。实验室成功与临床采用之间的差距反映了纳米医学设计中的更广泛挑战,包括对病变组织递送不佳、基于单一治疗载荷的策略在应对驱动CVDs的多层面炎症通路时疗效有限、NPs的免疫原性以及放大生产的可行性。解决这些障碍在CVDs中尤为关键,因为治疗成功取决于精准作用于多种分子和细胞驱动因素。本综述讨论心血管纳米医学不断演变的格局,聚焦四个方面。其一,概述NPs生物工程策略的进展,如改进的靶向部分、优化的理化性质以及对内源性和外源性刺激的响应性,这些策略增强了动脉粥样硬化、心肌梗死和卒中中的器官和细胞特异性递送。其二,讨论分析创新,这些创新改善了对NPs生物分布的表征和控制,使靶向更为合理。其三,评估治疗载荷,强调基于RNA和免疫调节的制剂如何代表迈向临床转化的重要一步。其四,概述应对安全性和可放大生产持续挑战的方法。这些发展共同为将NP设计原则转化为实用心血管疗法奠定了基础。随着靶向递送、临床安全性和生产可放大性持续进展,心血管纳米医学越来越有条件将临床前进展转化为改善患者结局的变革性成果。
Cardiovascular research IF 12.5 2026-10-26 PMID: 42929042
Carotid atherosclerotic plaque instability is a major cause of ischemic stroke. While current clinical guidelines for carotid endarterectomy rely primarily on stenosis severity and patient symptomatology, unstable plaques can cause strokes even with low to moderate stenosis, suggesting that factors beyond plaque stenosis may drive its instability. This study aimed to characterize the cellular and spatial features of plaque instability at both single-cell and subcellular resolution. single-cell RNA sequencing (scRNA-seq) was performed on carotid endarterectomy samples from patients with clinically and histologically classified stable or unstable plaques, consisting of more than 53,000 cells. Vascular smooth muscle cells (VSMCs), macrophages, and T-lymphocytes accounted for ∼85% of plaque-resident cells, with unstable plaques showing increased abundance of inflammatory synthetic VSMCs, GZMK+ cytotoxic T-lymphocytes, and antigen-presenting macrophages. In contrast, stable plaques were enriched in contractile and fibroblast-like VSMCs, alongside MRC1+ resident-like macrophages. To then spatially map these populations, CosMx™ high-plex spatial transcriptomics was integrated utilizing the unprecedented whole-transcriptome (∼18,934 targets) Human Discovery RNA panel. This revealed a distinct spatially disorganized plaque architecture in unstable plaques, characterized by infiltration of inflammatory synthetic VSMCs and effector T-lymphocytes distributed across both the fibrotic cap and lipid core, alongside distinct multicellular microenvironments enriched for adaptive immune engagement. This was in contrast to stable plaques, which exhibited more structured, macrophage-dominant spatial microenvironments and neighborhoods. We lastly profiled ∼90,000 paired peripheral blood mononuclear cells (PBMCs) to assess the plaque macroenvironment. PBMCs surrounding unstable plaques displayed exclusive enrichment of CD14+CD16+ intermediate monocytes and effector T-lymphocytes, which were depleted surrounding stable plaques. Ligand-receptor interaction analyses within CCL and CXCL-mediated pathways revealed enhanced immune-stromal signaling between PBMC-derived monocytes and plaque-resident VSMCs in the unstable plaque group, with coordinated chemokine-driven interactions indicating a shift toward VSMC- and T-lymphocyte mediated recruitment of circulating immune cells. These results demonstrate that carotid plaque instability is driven by spatially coordinated expansion of inflammatory VSMCs and effector immune cells within the plaque and from the circulation, with a shift from predominantly innate immune-dominant characteristics in stable plaques toward adaptive immune-enriched responses in unstable conditions. This integrated single-cell and spatial transcriptomic approach refines an integrated immune-stromal framework linking local plaque remodeling with systemic immune activation, highlighting key tissue-resident and circulating contributors to instability and establishing a foundation for mechanism-informed diagnostics and targeted therapeutic strategies beyond stenosis severity.
中文摘要:颈动脉粥样硬化斑块不稳定是缺血性卒中的主要原因。当前颈动脉内膜切除术的临床指南主要依据狭窄程度和患者症状,但不稳定斑块即使在低至中度狭窄时也可导致卒中,提示除斑块狭窄外还有其他因素驱动其不稳定。该工作旨在单细胞和亚细胞分辨率刻画斑块不稳定的细胞与空间特征。对临床和组织学分类为稳定或不稳定斑块患者的颈动脉内膜切除样本进行单细胞RNA测序,共超过53,000个细胞。血管平滑肌细胞、巨噬细胞和T淋巴细胞约占斑块驻留细胞的85%,不稳定斑块中炎症性合成型血管平滑肌细胞、GZMK+细胞毒性T淋巴细胞和抗原提呈巨噬细胞增多。稳定斑块则富集收缩型和成纤维细胞样血管平滑肌细胞以及MRC1+驻留样巨噬细胞。为空间定位这些细胞群体,整合CosMx™高重空间转录组,采用涵盖约18,934个靶标的Human Discovery RNA全转录组检测panel。不稳定斑块显示空间结构紊乱,炎症性合成型血管平滑肌细胞和效应T淋巴细胞浸润并分布于纤维帽和脂质核心,同时存在富集适应性免疫参与的多细胞微环境。稳定斑块则呈现更有结构、以巨噬细胞为主的空间微环境和邻域。最后分析约90,000个配对外周血单个核细胞以评估斑块宏观环境。不稳定斑块周围的外周血单个核细胞独有富集CD14+CD16+中间型单核细胞和效应T淋巴细胞,而稳定斑块周围则减少。CCL和CXCL介导通路内的配体-受体互作分析显示,不稳定斑块组中外周血单个核细胞来源单核细胞与斑块驻留血管平滑肌细胞之间免疫-基质信号增强,趋化因子驱动的协调互作提示向血管平滑肌细胞和T淋巴细胞介导的循环免疫细胞募集转变。这些结果表明颈动脉斑块不稳定由斑块内及循环来源的炎症性血管平滑肌细胞和效应免疫细胞空间协调扩增驱动,稳定斑块以先天免疫主导的特征向不稳定状态的适应性免疫富集反应转变。整合单细胞和空间转录组方法完善了连接局部斑块重塑与系统性免疫激活的免疫-基质框架,突出关键组织驻留和循环来源的贡献因素,为超越狭窄程度的机制导向诊断和靶向治疗策略奠定基础。
Molecular biomedicine IF 13.0 2026-10-24 PMID: 42920026
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death that is driven by lipid peroxidation. In the past decade, it has emerged as a core pathogenic mechanism in a wide range of human diseases, such as neurodegenerative disorders, cardiovascular disease, cancer, and notably, reproductive dysfunction. This review provides a comprehensive overview of the molecular mechanisms underlying ferroptosis with a specific focus on the System Xc⁻-GSH-GPX4 axis, iron metabolism, lipid peroxidation, and the regulatory roles of key modulators such as Nrf2, ACSL4, and CISD2. This review also explores the physiological roles of ferroptosis in development, tissue homeostasis, and immune regulation, as well as its pathological contributions to obesity, diabetes mellitus, atherosclerosis, neurodegeneration, stroke, cancer, infectious diseases, and reproductive disorders. A substantial part of this review discusses the role of ferroptosis in the pathogenesis of reproductive disorders, such as male reproductive pathologies, including varicocele, testicular ischemia-reperfusion, cryptorchidism, oligospermia, erectile dysfunction, and testicular cancer, and female pathologies like primary ovarian insufficiency, polycystic ovary syndrome, endometriosis, ovarian cancer, and pre-eclampsia. Moreover, the interplay between ferroptosis and immune dysfunction in reproductive tract infections was highlighted. Furthermore, we evaluated current biomarkers, emerging therapeutic strategies, and key translational challenges, highlighting the promise of ferroptosis-modulating agents for novel diagnostic and therapeutic interventions in reproductive medicine and beyond.
中文摘要:铁死亡是一种铁依赖、非凋亡性的调节性细胞死亡形式,由脂质过氧化驱动。过去十年,它已成为多种人类疾病的核心致病机制,涉及神经退行性疾病、心血管疾病、癌症,尤其是生殖功能障碍。本综述全面概述铁死亡的分子机制,重点讨论System Xc⁻-GSH-GPX4轴、铁代谢、脂质过氧化,以及Nrf2、ACSL4和CISD2等关键调控因子的调节作用。本综述还探讨铁死亡在发育、组织稳态和免疫调节中的生理作用,以及它在肥胖、糖尿病、动脉粥样硬化、神经退行性变、卒中、癌症、感染性疾病和生殖障碍中的病理贡献。综述的较大篇幅讨论铁死亡在生殖障碍发病机制中的作用,包括男性生殖病理如精索静脉曲张、睾丸缺血再灌注、隐睾、少精症、勃起功能障碍和睾丸癌,以及女性病理如原发性卵巢功能不全、多囊卵巢综合征、子宫内膜异位症、卵巢癌和子痫前期。生殖道感染中铁死亡与免疫功能障碍之间的相互作用亦被强调。本综述进一步评估现有生物标志物、新兴治疗策略和关键转化挑战,突出铁死亡调节剂在生殖医学及其他领域新型诊断和治疗干预中的前景。

2痴呆与认知障碍 (12篇)

临床研究 (2篇)

Nature IF 56.1 2026-10-28 PMID: 42951976
Alzheimer's disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60-80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and found that genes upregulated in microglia and downregulated in neurons in cases compared with controls were enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a SNP heritability of 16%, nearly threefold higher than previous estimates. Together, our findings show that the common-variant contribution to AD has been substantially underestimated, and reveal new molecular and cellular mechanisms as well as specific targets for future drug development research.
中文摘要:阿尔茨海默病(AD)是痴呆最常见的病因,预计2050年全球病例数将达到1.53亿。AD具有高度遗传性,基于双生子的遗传力估计为60-80%。尽管预测AD存在1200个因果位点,近期两项研究已发现约80个位点与AD相关。基于SNP的遗传力估计偏低,促使有人提出几乎不再有更多常见变异风险可发现。我们分析了来自不同祖先的109479例病例、74141例代理病例、2131799例对照和499708例代理对照的数据,在多祖先分析中识别出118个位点,在祖先特异性分析中又识别出9个位点,其中48个为新位点。我们识别出新的AD风险基因,对潜在药物靶点进行优先级排序,并发现与对照相比,病例中小胶质细胞中上调、神经元中下调的基因富集了AD相关遗传风险。我们改进了多基因预测,并估计SNP遗传力为16%,接近此前估计的三倍。这些发现表明,常见变异对AD的贡献被显著低估,并揭示了新的分子和细胞机制以及未来药物开发研究的特定靶点。
Ageing research reviews IF 15.5 2026-10-24 PMID: 42926022
Cognitive reserve (CR) is a broad framework for explaining why individuals differ in cognitive functioning in the face of aging and neuropathology. One influential mechanistic account proposes that cognitively demanding life experiences such as education, occupational complexity, and cognitively stimulating activities augment a domain-general cognitive capacity that subsequently provides resilience. We refer to this more specific claim as cognitive reserve augmentation (CRA). This narrative and conceptual review evaluates the inferential strength of the evidence for CRA, emphasizing prospective cohort studies as the strongest available observational design for evaluating causal hypotheses. Across meta-analyses, several putative reserve-building experiences show consistent protective associations; however, comparison across prospective cohort studies reveals a striking asymmetry: whereas education, occupational complexity, and cognitively stimulating activities predict reduced risk or delayed clinical diagnosis of dementia, bilingualism-also proposed as a reserve-building cognitive experience-does not. This pattern constrains the assumption that diverse cognitive experiences augment a common reserve mechanism. Life-course evidence further indicates that associations between traditional CR proxies and later cognitive functioning can be substantially attenuated when earlier cognitive ability is measured directly. We argue that these findings are compatible with multiple pathways involving selection, correlated socioeconomic and health factors, domain-specific knowledge and expertise, processing efficiency, and effects on brain and physical health, as well as possible changes in cognitive capacity. Distinguishing among these alternatives requires specifying what experience is proposed to change, which experiences should and should not produce that change, and which outcomes would challenge the proposed mechanism. CR may therefore remain useful as a broad descriptive framework even when evidence for CRA or another specified reserve mechanism is incomplete.
中文摘要:认知储备(CR)是一个宽泛框架,用于解释个体在衰老和神经病理条件下认知功能为何存在差异。一种有影响力的机制解释提出,教育、职业复杂性、认知刺激活动等对认知要求高的生活经历会增强一种领域一般性认知能力,这种能力随后提供韧性。我们将这一更具体的说法称为认知储备增强(CRA)。这篇叙述性与概念性综述评估CRA证据的推断强度,强调前瞻性队列研究是现有观察性设计中评估因果假设最强的一种。各项荟萃分析中,若干被认为可构建储备的经历显示出一致的保护性关联;然而,前瞻性队列研究之间的比较呈现出显著不对称:教育、职业复杂性和认知刺激活动可预测痴呆风险降低或临床诊断延迟,而被同样提出为储备构建认知经历的双语则不然。这一模式限制了「多样认知经历会增强共同储备机制」的假设。生命历程证据进一步表明,当直接测量早先认知能力时,传统CR代理指标与后来认知功能之间的关联可明显减弱。我们认为,这些发现与多条路径相容,涉及选择、相关的社会经济与健康因素、领域特定知识与专长、加工效率、对大脑和身体健康的影响,以及认知能力可能发生的变化。要区分这些替代解释,需要说明所提出的经历改变什么、哪些经历应当或不应产生该改变,以及哪些结局会挑战所提出的机制。因此,即使CRA或其他特定储备机制的证据尚不完整,CR作为宽泛的描述性框架仍可能有用。

基础研究 (10篇)

Molecular psychiatry IF 10.4 2026-10-30 PMID: 42963367
Mitochondrial complex IV (CIV) is an integral part of the mitochondrial electron transport chain (ETC) and plays a pivotal role in maintaining mitochondrial function. In contrast to the long-standing recognition of its dysfunction in Alzheimer's disease (AD), the exact role of CIV deficit in the pathogenesis of this neurodegenerative disorder remains poorly defined. In this study, by incorporating clinical resources, mouse- and human-based models of AD risk, and a genetic approach to bypass defective CIV via the ectopic expression of alternative oxidase (AOX), we examined whether CIV deficits are a pathogenic driver of or a beneficial adaptation to AD-associated pathologies. Our results showed a clinicopathological association between neuronal CIV dysfunction and pathological characteristics of AD. Further experiments linked defective CIV to the development of mitochondrial dysfunction and synaptic loss in the tested mouse- and human-based models of AD risk. In addition, a reciprocal relationship between CIV dysfunction and amyloid pathology was determined. Lastly, a proteome-wide association study (PWAS) using genetic data from large-scale AD cohorts identified that downregulation of COX11, a crucial CIV assembly factor, confers susceptibility to AD risk. Collectively, our findings suggest that CIV dysfunction is a detrimental pathology contributing to AD-associated mitochondrial and neuronal damage. The dual role of CIV dysfunction, both as a consequence of and a contributor to amyloid toxicity in AD pathogenesis, further justifies the therapeutic potential of strategies targeting CIV deficits to diversify the tools for prevention and treatment of this neurodegenerative disorder.
中文摘要:线粒体复合物IV(CIV)是线粒体电子传递链(ETC)的组成部分,在维持线粒体功能中起关键作用。尽管长期认识到其在阿尔茨海默病(AD)中的功能障碍,CIV缺陷在该神经退行性疾病发病机制中的确切作用仍不清楚。本研究结合临床资源、基于小鼠和人类的AD风险模型,以及通过异位表达替代氧化酶(AOX)绕过缺陷CIV的遗传学方法,考察CIV缺陷是AD相关病理的致病驱动因素还是有益适应。结果显示,神经元CIV功能障碍与AD病理特征之间存在临床病理关联。进一步实验在受试的小鼠和人类AD风险模型中,将缺陷CIV与线粒体功能障碍和突触丢失的发生联系起来。研究还确定了CIV功能障碍与淀粉样蛋白病理之间的双向关系。利用大规模AD队列遗传数据的全蛋白质组关联研究(PWAS)发现,CIV关键组装因子COX11下调赋予AD风险易感性。这些发现提示CIV功能障碍是一种有害病理,促成AD相关的线粒体和神经元损伤。CIV功能障碍在AD发病机制中既是淀粉样蛋白毒性的结果,也是其促进因素,这种双重作用进一步支持靶向CIV缺陷策略的治疗潜力,可丰富该神经退行性疾病的预防和治疗工具。
Neuron IF 16.9 2026-10-30 PMID: 42962664
A growing body of evidence implicates the menopausal transition as a neurobiological inflection point in women's brain aging and Alzheimer's disease (AD) vulnerability. Menopause is a midlife neuroendocrine transition characterized by a decline in sex steroid hormones and widespread systemic effects. The brain is not a passive recipient of ovarian hormones but an active endocrine-sensing organ. Menopause, however, does not act in isolation: the ovarian-brain axis is established embryonically, activated at puberty, remodeled during pregnancy and postpartum, and reconfigured during the menopausal transition, with implications for later-life brain aging. This review places menopause within a lifespan neuroendocrine framework, examining mechanisms by which the transition may influence the brain, including altered hormone signaling, bioenergetics, synaptic plasticity, neurovascular function, inflammation, and AD-related pathology. It then reviews evidence linking menopausal timing to neurobiological and AD vulnerability, discusses estrogen therapy, and considers menopause as a biologically plausible window for risk stratification and prevention.
中文摘要:越来越多的证据提示,绝经过渡是女性脑老化与阿尔茨海默病(AD)易感性的神经生物学转折点。绝经是一种中年神经内分泌转变,以性类固醇激素下降及广泛的全身性影响为特征。脑并非卵巢激素的被动接受者,而是主动的内分泌感知器官。绝经并非孤立起作用:卵巢—脑轴在胚胎期建立,青春期激活,妊娠与产后重塑,并在绝经过渡期重新配置,进而影响晚年脑老化。本综述将绝经置于贯穿生命周期的神经内分泌框架中,考察该转变影响脑的可能机制,包括激素信号改变、生物能量学、突触可塑性、神经血管功能、炎症以及AD相关病理。随后综述将绝经时点与神经生物学及AD易感性相联系的证据,讨论雌激素治疗,并将绝经视为风险分层与预防的一个生物学上合理的窗口。
Ageing research reviews IF 15.5 2026-10-29 PMID: 42956845
Alzheimer's disease (AD) is characterized by marked heterogeneity in the timing and extent of neuronal dysfunction and degeneration. Specific neuronal populations, including entorhinal cortex layer II stellate cells, hippocampal CA1 pyramidal neurons, basal forebrain cholinergic neurons, locus coeruleus noradrenergic neurons, and prefrontal parvalbumin interneurons, show different combinations of functional, pathological, and degenerative vulnerability during disease progression. The strength and nature of this evidence, however, vary across neuronal populations and between human studies and experimental models. Selective vulnerability is therefore unlikely to reflect a single cell-type-specific mechanism. Instead, pathological stress in AD interacts with intrinsic cellular properties, circuit organization, and the local microenvironment. Metabolic stress, axonal transport impairment, excitotoxicity and Ca²⁺ dysregulation, neuroinflammation, lipid dysregulation and ferroptotic stress, and proteostasis failure may consequently produce distinct functional and degenerative outcomes across neuronal populations. Advances in transcriptomics, neuropathology, multimodal imaging, and circuit-level analyses are also identifying molecular, regional, and functional measures associated with early involvement of vulnerable neuronal systems, although validated cell-type-specific biomarkers remain limited. In this Review, we integrate these findings to examine the evidence for selective neuronal vulnerability, the mechanisms that may modify neuronal susceptibility, and their implications for biomarker development and therapy. We further consider how vulnerability-informed strategies could complement pathology-directed therapies by aligning therapeutic mechanisms with prominent cellular or circuit dysfunction and disease stage. This perspective may help explain the spatial and temporal heterogeneity of AD and guide more biologically informed approaches to early detection and intervention.
中文摘要:阿尔茨海默病(AD)在神经元功能障碍与变性发生的时间和程度上表现出明显的异质性。内嗅皮层II层星形细胞、海马CA1锥体神经元、基底前脑胆碱能神经元、蓝斑去甲肾上腺素能神经元以及前额叶小清蛋白中间神经元等特定神经元群体,在疾病进程中呈现出功能、病理与变性易感性的不同组合。这些证据的强度与性质在不同神经元群体之间、以及人类研究与实验模型之间并不一致。选择性易感性因此不太可能由单一细胞类型特异的机制解释。AD中的病理应激与细胞内在属性、环路组织和局部微环境相互作用。代谢应激、轴突运输障碍、兴奋性毒性与Ca²⁺调控异常、神经炎症、脂质调控异常与铁死亡应激、蛋白质稳态失衡,可能因此在不同神经元群体中产生各异的功能与变性结局。转录组学、神经病理学、多模态成像与环路水平分析的进展,正在识别与易感神经元系统早期受累相关的分子、区域和功能指标,但经充分验证的细胞类型特异性生物标志物仍然有限。本综述整合这些发现,考察选择性神经元易感性的证据、可能改变神经元易感程度的机制,及其对生物标志物开发和治疗的意义。并进一步讨论以易感性为导向的策略如何通过使治疗机制与突出的细胞或环路功能障碍及疾病阶段相匹配,补充针对病理的治疗。这一视角可能有助于解释AD在空间和时间上的异质性,并为早期检测和干预提供更具生物学依据的路径。
Cell IF 45.1 2026-10-29 PMID: 42956716
In this issue of Cell, Brioschi et al. identify cellular musculoaponeurotic fibrosarcoma (cMAF) as a key regulator of brain perivascular macrophages that supports cerebrovascular function through insulin-like growth factor 1 (IGF1) production. This cMAF-IGF1 program is enhanced in Alzheimer's disease (AD), potentially reflecting a protective response that is lost in APOE4 carriers.
中文摘要:在本期 Cell 中,Brioschi 等人将细胞型肌腱膜纤维肉瘤蛋白(cMAF)鉴定为脑血管周围巨噬细胞的关键调控因子,其通过产生胰岛素样生长因子1(IGF1)支持脑血管功能。该 cMAF-IGF1 程序在阿尔茨海默病中增强,可能反映一种在 APOE4 携带者中丧失的保护性反应。
Cell IF 45.1 2026-10-29 PMID: 42600613
Brain perivascular macrophages maintain brain physiology, yet their transcriptional regulators and functions in health and disease remain unclear. Using single-cell multi-omics and functional experiments, we identify cellular musculoaponeurotic fibrosarcoma oncogene (cMAF) as a key transcription factor for brain perivascular macrophages, and conditional deletion of cMAF disrupts their phenotype in vivo. Functionally, cMAF drives insulin-like growth factor-1 (IGF1) expression in perivascular macrophages, enabling communication with endothelial cells. Consistently, cMAF deletion in perivascular macrophages causes transcriptional alterations in cerebral arteries, affecting vascular functions. Notably, cMAF emerges as the main transcription factor for human perivascular macrophages, suggesting conservation of this transcriptional module. During Alzheimer's disease (AD), human perivascular macrophages upregulate cMAF and IGF1 to enhance communication with vascular cells, and this response is abrogated in APOE4 carriers. Lastly, we explore an uncharacterized polymorphism in cMAF, providing evidence that the cMAF program is protective against AD. Targeting cMAF in perivascular macrophages may offer new therapeutic strategies for neurodegenerative and cerebrovascular diseases.
中文摘要:脑血管周围巨噬细胞维持脑生理,但其转录调控因子及在健康与疾病中的功能仍不清楚。我们利用单细胞多组学与功能实验,鉴定细胞性肌腱膜纤维肉瘤癌基因(cMAF)为脑血管周围巨噬细胞的关键转录因子,条件性敲除cMAF可在体内破坏其表型。功能上,cMAF驱动血管周围巨噬细胞表达胰岛素样生长因子-1(IGF1),使其能够与内皮细胞通讯。与此一致,血管周围巨噬细胞中敲除cMAF引起脑动脉转录改变,影响血管功能。cMAF也是人血管周围巨噬细胞的主要转录因子,提示该转录模块具有保守性。在阿尔茨海默病(AD)中,人血管周围巨噬细胞上调cMAF和IGF1以增强与血管细胞的通讯,而该反应在APOE4携带者中消失。最后,我们探索了cMAF中一个未表征的多态性,提供证据表明cMAF程序对AD具有保护作用。靶向血管周围巨噬细胞中的cMAF可能为神经退行性疾病和脑血管病提供新的治疗策略。
Translational neurodegeneration IF 19.1 2026-10-28 PMID: 42958598
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and Parkinson's disease (PD) are characterized by the accumulation of intrinsically disordered proteins (IDPs), including amyloid-β (Aβ), tau, and α-synuclein (αSyn). These proteins disrupt neuronal homeostasis through toxic aggregation, impaired proteostasis, and progressive neurodegeneration, in part via dysfunction of the autophagy-lysosomal pathway (ALP). A central feature of this impairment is defective vacuolar-type (H+)-ATPase (V-ATPase) function, leading to lysosomal deacidification and reduced degradative capacity. Pathological IDP species converge on V-ATPase through direct interactions with its subunits or by perturbing its assembly, while also exerting protein-specific effects, including lysosomal membrane destabilization, impaired hydrolase activity, and disrupted endolysosomal trafficking. These combined mechanisms create a reciprocal relationship between lysosomal dysfunction and IDP accumulation, in which impaired lysosomal degradation further promotes the persistence and aggregation of pathological IDP species. This review synthesizes current insights into the molecular interplay between IDPs and lysosomal acidification across AD, FTD, and PD, and highlights how these processes contribute to disease progression. We further discuss emerging therapeutic strategies aimed at restoring lysosomal function. These findings underscore lysosomal dysfunction as a common feature of IDP-driven neurodegeneration and a potential therapeutic target across these disorders.
中文摘要:阿尔茨海默病(AD)、额颞叶痴呆(FTD)和帕金森病(PD)等神经退行性疾病以内在无序蛋白(IDPs)的积聚为特征,包括淀粉样β蛋白(Aβ)、tau蛋白和α-突触核蛋白(αSyn)。这些蛋白通过毒性聚集、蛋白稳态受损和进行性神经退行改变破坏神经元稳态,部分经由自噬-溶酶体通路(ALP)功能障碍实现。该损伤的核心特征是液泡型(H+)-ATP酶(V-ATPase)功能缺陷,导致溶酶体去酸化与降解能力下降。病理性IDP种类通过直接与V-ATPase亚基相互作用或干扰其组装而汇聚于V-ATPase,同时产生蛋白特异性效应,包括溶酶体膜失稳、水解酶活性受损和内涵体-溶酶体运输紊乱。这些机制共同在溶酶体功能障碍与IDP积聚之间形成互为因果的关系,其中溶酶体降解受损进一步促进病理性IDP种类的持续存在与聚集。本综述综合当前关于AD、FTD和PD中IDPs与溶酶体酸化分子相互作用的认识,并强调这些过程如何推动疾病进展。我们进一步讨论旨在恢复溶酶体功能的新兴治疗策略。这些发现强调溶酶体功能障碍是IDP驱动神经退行性变的共同特征,也是跨这些疾病的潜在治疗靶点。
Journal of the American Chemical Society IF 16.6 2026-10-28 PMID: 42954557
Early diagnosis of Alzheimer's disease (AD) is impeded by the subtle, heterogeneous nature of fluid biomarkers during the disease's initial phases. Current detection tools, which target single biomarkers, often lack the necessary sensitivity and specificity for presymptomatic screening. To address this, we develop a machine learning-informed supramolecular sensor array that leverages a holistic design to overcome the limitations of "lock-and-key" recognition. By engineering macrocyclic receptors with semiselective properties, we generate a competitive signal transduction process characterized by multiple equilibria and nonlinear responses. This design confers high-dimensional cross-reactivity, delineating distinct fluorescent fingerprints for specific AD stages. The array achieves 100% diagnostic accuracy in cerebrospinal fluid from 1-month-old rat models─predating conventional ELISA detection by 3 months and behavioral symptoms by 4 months. Crucially, the array identifies human patients at the subjective cognitive decline stage with >95% accuracy. This work presents a clinically viable tool for early AD diagnosis and establishes a generalizable, modular framework for multiplexed biomarker analysis in neurodegenerative diseases.
中文摘要:阿尔茨海默病(AD)的早期诊断受制于疾病初期体液生物标志物细微且异质的特点。现有检测工具多针对单一生物标志物,用于症状前筛查时常缺乏足够的敏感性和特异性。为此,我们开发了一种机器学习辅助的超分子传感器阵列,借助整体设计克服「锁钥」式识别的局限。通过对具有半选择性的大环受体进行工程化设计,构建出以多重平衡和非线性响应为特征的竞争性信号转导过程。该设计赋予阵列高维交叉反应性,可区分特定AD阶段的不同荧光指纹。该阵列在1月龄大鼠模型的脑脊液中实现100%诊断准确率,比常规ELISA检测提前3个月,比行为症状出现提前4个月。该阵列还能以超过95%的准确率识别处于主观认知下降阶段的人类患者。这项工作提供了可用于早期AD诊断的临床可行工具,并为神经退行性疾病中的多重生物标志物分析建立了可推广的模块化框架。
Advanced drug delivery reviews IF 21.0 2026-10-28 PMID: 42950990
This review examines the emerging role of human brain microphysiological systems (HBMPS) in recapitulating diseases and evaluating their translational potential and limitations for Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). Both disorders differ in underlying cause, but converge on shared downstream pathophysiology such as tau pathology, neuroinflammation, and blood-brain barrier (BBB) dysfunction. We review the critical pathophysiological features relevant to modeling AD and CTE and introduce HBMPS platforms/validation strategies as potential tools for evaluating therapeutic compounds as well as drug-delivery approaches. We also provide a systematic comparison of the relative advantages and disadvantages of 2D, HBMPS, Xenograft, and animal models and discuss the future potential of HBMPS's drug-testing platform. We further discuss current challenges of HBMPS related to drug testing, engineering extracellular matrix for tissue chips, and BBB penetration in AD and CTE. We suggest future integration of organoid xenografts and AI-assisted frameworks to enhance pathophysiological fidelity/drug predictive capability and to bridge the gap between HBMPS and animal models. In summary, this paper reviews HBMPS technologies as future translation platforms' direction for drug screening and delivery, while providing current limitations and challenges including model validation, reproducibility, and standardized regulatory bases required for preclinical success for HBMPS use. Rather than comparing biological complexity with translational validity, this review applies a decision-oriented framework that distinguishes mechanistic fidelity, comparative candidate ranking, predictive validation, investigational new drug (IND)-supporting use, and replacement of a defined animal test. For each use, we identify quantitative transport, exposure-response, pharmacodynamic, safety, and reproducibility evidence required to support an advance, redesign, or go/stop decision.
中文摘要:人脑微生理系统(HBMPS)在重现疾病、评估转化潜力与局限方面的新兴作用,正被置于阿尔茨海默病(AD)与慢性创伤性脑病(CTE)背景下审视。两类疾病的根本病因不同,却在tau病理、神经炎症和血脑屏障(BBB)功能障碍等下游病理生理过程上趋同。文章梳理了与AD和CTE建模相关的关键病理生理特征,并介绍HBMPS平台及验证策略,作为评估治疗化合物和药物递送方法的潜在工具。文章系统比较二维模型、HBMPS、异种移植模型和动物模型的相对优缺点,讨论HBMPS药物测试平台的未来潜力。文章还讨论HBMPS在药物测试、组织芯片细胞外基质工程以及AD和CTE中BBB穿透方面面临的当前挑战。文章建议未来整合类器官异种移植与人工智能辅助框架,以提升病理生理保真度和药物预测能力,并弥合HBMPS与动物模型之间的差距。文章将HBMPS技术视为未来药物筛选和递送转化平台的发展方向,同时指出其当前局限与挑战,包括模型验证、可重复性以及HBMPS用于临床前研究取得成功所需的标准化监管基础。文章不以生物复杂性与转化有效性作对照,而采用决策导向框架,区分机制保真度、候选物比较排序、预测性验证、支持研究性新药(IND)申报的用途,以及替代既定的动物试验。针对每种用途,文章明确了支持推进、重新设计或继续/停止决策所需的定量转运、暴露-反应、药效动力学、安全性和可重复性证据。
Autophagy IF 18.6 2026-10-28 PMID: 42922083
The network of transcription factors (TFs) is an integral component of executing macroautophagy/autophagy-lysosome gene expression to maintain cellular homeostasis. Across metazoans, conserved TFs, particularly the helix-loop-helix factor TFEB, convert upstream signals into specific genetic programs through mechanisms ranging from DNA recognition and chromatin remodeling to biomolecular condensates. The dysregulation of TF-governed gene programming disrupts the progression of metabolic disease and cancer, highlighting that dissection of transcriptional regulation makes it a promising therapeutic target. Consequently, instead of indirectly modulating the pathways in which they are involved, targeting these essential TFs directly is becoming a new trend for pharmaceutical development. In this review, we systematically elucidate current mechanisms of the TF-driven autophagic transcriptome, and summarize current small molecules targeting these TFs in various disease.Abbreviations: AD: Alzheimer disease; AFF4: ALF transcription elongation factor 4; AKT: AKT serine/threonine kinase; AMPK: AMP-activated protein kinase; AR: androgen receptor; ATF4: activating transcription factor 4; ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; BRD4: bromodomain containing 4; CRC: colorectal cancer; CREBBP/CBP: CREB binding lysine acetyltransferase; CTNNB1/β-catenin: catenin beta 1; DBD: DNA-binding domain; DDIT3: DNA damage inducible transcript 3; DRAM1: DNA damage regulated autophagy modulator 1; E2F1: E2F transcription factor 1; EHMT2/G9a: euchromatic histone lysine methyltransferase 2; EO: eltrombopag; EP300/p300: EP300 lysine acetyltransferase; ERBB2: erb-b2 receptor tyrosine kinase 2; FOXO3: forkhead box O3; GSH: glutathione; GSK3B/GSK3β: glycogen synthase kinase 3 beta; HD: Huntington disease; KAT2B/GCN5: lysine acetyltransferase 2B; HMGB1: high mobility group box 1; KDACs: lysine deacetylases; KEAP1: kelch like ECH associated protein 1; KLF4: KLF transcription factor 4; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPK: mitogen-activated protein kinase; MITF: melanocyte inducing transcription factor; MTORC1: mechanistic target of rapamycin kinase complex 1; MiT/TFE: microphthalmia-transcription factor E; MYC: proto-oncogene, bHLH transcription factor; NDs: neurodegenerative disorders; NFE2L2/NRF2: NFE2 like bZIP transcription factor 2; P-TEFb: positive transcription elongation factor b; PARP1: poly(ADP-ribose) polymerase 1; PD: Parkinson disease; PIC: pre-initiation complex; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PTMs: post-translational modifications; POLR2: RNA polymerase II; SIRT1: sirtuin 1; SNAI2: snail family transcriptional repressor 2; STAT3: signal transducer and activator of transcription 3; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; TFs: transcription factors; TNKS: tankyrase; TP53: tumor protein p53; ULK1: unc-51 like autophagy activating kinase 1; YWHA/14-3-3: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; YY1: YY1 transcription factor; ZKSCAN3: zinc finger with KRAB and SCAN domains 3.
中文摘要:转录因子网络是执行巨自噬/自噬-溶酶体基因表达以维持细胞稳态的组成部分。在后生动物中,保守的转录因子,尤其是螺旋-环-螺旋转录因子TFEB,通过从DNA识别、染色质重塑到生物分子凝聚体等机制,将上游信号转化为特定基因程序。转录因子调控的基因编程失调会扰乱代谢性疾病和癌症的进展,说明解析转录调控使其成为有前景的治疗靶点。因此,直接靶向这些关键转录因子而非间接调节其参与的通路,正成为药物开发的新趋势。本综述系统阐述转录因子驱动自噬转录组的现有机制,并总结当前在各种疾病中靶向这些转录因子的小分子。
Neuron IF 16.9 2026-10-27 PMID: 42945962
Although tau pathology correlates with cognitive decline in Alzheimer's disease (AD), some individuals exhibit resilience by maintaining cognitive function. The mechanisms enabling this protection, particularly before widespread cortical degeneration occurs, remain elusive. Here, we identify a dynamic interplay between cellular vulnerability and circuit-level resilience that shapes cognitive outcomes in AD. Tau accumulation in the Edinger-Westphal nucleus (EW) impairs attention by inducing hypoexcitability in CART+ neurons via Kcnma1 upregulation, a vulnerability predictive of future decline in both 3×Tg-AD mice and AD patients. Conversely, a subset of AD mice with heightened exploratory behavior activates a compensatory medial parabrachial (mPB)-EW circuit, mediated by substance P-Tacr1 signaling, which sustains CART+ neuron function and delays cognitive deterioration. These findings reveal resilience as an active state enabled by trait-linked circuit plasticity that balances cellular vulnerability, defining multilevel targets for early intervention.
中文摘要:尽管tau病理与阿尔茨海默病(AD)的认知下降相关,部分个体仍能维持认知功能而表现出韧性。这种保护机制,尤其在大范围皮层退变发生之前,仍不清楚。我们识别出细胞脆弱性与环路层面韧性之间的动态相互作用塑造AD认知结局。Edinger-Westphal核(EW)内tau积聚通过Kcnma1上调诱导CART+神经元低兴奋性,损害注意力;这一脆弱性可预测3×Tg-AD小鼠和AD患者未来的认知下降。相反,一部分探索行为增强的AD小鼠激活了由P物质-Tacr1信号介导的代偿性内侧臂旁核(mPB)-EW环路,维持CART+神经元功能并延缓认知恶化。这些发现表明韧性是一种主动状态,由特质相关环路可塑性促成,平衡细胞脆弱性,为早期干预界定多层级靶点。

3帕金森病与运动障碍 (6篇)

基础研究 (6篇)

Ageing research reviews IF 15.5 2026-10-30 PMID: 42962772
Oxidative stress and lipid peroxidation are increasingly recognized as age-related drivers of neurodegeneration, with Parkinson's disease (PD) representing a condition of heightened vulnerability. Among lipid peroxidation products, reactive aldehydes including 4-hydroxy-2-nonenal, malondialdehyde, acrolein, 4-hydroxy-2-hexenal, and crotonaldehyde have emerged not only as biomarkers of oxidative damage, but also as active mediators of neuronal dysfunction. Owing to their electrophilic nature, these aldehydes interact with nucleophilic residues, including cysteine, lysine, and histidine, forming covalent adducts that impair proteostasis, mitochondrial function, and redox signaling. Under physiological conditions, lipid peroxidation-derived aldehydes (LPDAs) are detoxified through glutathione-dependent conjugation and oxidoreductase-mediated metabolism. However, ageing progressively impairs these protective systems, promoting aldehyde accumulation and increasing dopaminergic vulnerability. We propose that PD may reflect, at least in part, an age-dependent impairment of aldehyde detoxification in addition to increased reactive oxygen species production. Although current experimental and clinical evidence supports the pathogenic relevance of some LPDAs in PD, antioxidant-based interventions have yielded inconsistent clinical outcomes. Within this framework, antioxidant strategies can be interpreted according to their functional impact on aldehyde burden. Approaches aimed at restoring glutathione homeostasis or activating Nrf2-dependent pathways may enhance endogenous detoxification systems and thereby support aldehyde clearance. More directly targeted approaches include strategies that enhance aldehyde metabolism, such as pharmacological activation of ALDH2. Overall, shifting the therapeutic focus from radical scavenging to the modulation of aldehyde burden through combined upstream and downstream interventions represents a promising but still underexplored avenue in PD and age-related neurodegenerative disorders that warrants further validation in clinical settings.
中文摘要:氧化应激和脂质过氧化日益被视为年龄相关神经退行性变的驱动因素,帕金森病(PD)则是脆弱性升高的情形。脂质过氧化产物中,4-羟基-2-壬烯醛、丙二醛、丙烯醛、4-羟基-2-己烯醛和巴豆醛等反应性醛类不仅作为氧化损伤的生物标志物出现,也作为神经元功能障碍的主动介质。由于具有亲电性,这些醛类与半胱氨酸、赖氨酸和组氨酸等亲核残基相互作用,形成共价加合物,损害蛋白质稳态、线粒体功能和氧化还原信号。生理条件下,脂质过氧化衍生醛类(LPDAs)通过谷胱甘肽依赖的共轭和氧化还原酶介导的代谢被解毒。衰老逐渐损害这些保护系统,促进醛类蓄积并增加多巴胺能脆弱性。我们提出,PD至少部分反映了除活性氧产生增加之外的、年龄依赖的醛类解毒受损。尽管现有实验和临床证据支持某些LPDAs在PD中的致病相关性,基于抗氧化剂的干预却产生了不一致的临床结局。在此框架内,抗氧化策略可按其对醛负荷的功能影响来理解。旨在恢复谷胱甘肽稳态或激活Nrf2依赖通路的策略可能增强内源性解毒系统,从而支持醛类清除。更直接靶向的策略包括增强醛类代谢的方法,如药理学激活ALDH2。将治疗重点从自由基清除转向通过上游和下游联合干预调节醛负荷,是PD和年龄相关神经退行性疾病中有前景但仍探索不足的途径,值得在临床环境中进一步验证。
Science advances IF 13.9 2026-10-30 PMID: 42962009
Chaperone-mediated autophagy (CMA), regulated by its lysosomal receptor LAMP2A, is a key pathway for αSynuclein (αSyn) clearance and a direct target of αSyn-related neurotoxicity. Rodent studies show that LAMP2A enhancement reverses neurodegeneration, whereas its deficiency accelerates pathology. To test translational relevance, we examined whether increasing LAMP2A expression in nonhuman primates could mitigate α-synucleinopathy induced by injections of Parkinson's disease patient-derived Lewy body (LB) extract. Increasing LAMP2A expression protected nigral dopaminergic neurons from LB-induced αSyn neurodegeneration, delayed the formation and release of pathology-related αSyn species, and evoked a beneficial effect on motor behavior and on cognitive functions of the primate model. Our findings provide preliminary preclinical evidence supporting CMA enhancement as a therapeutic strategy for αSynucleinopathies.
中文摘要:分子伴侣介导的自噬(CMA)受其溶酶体受体LAMP2A调控,是αSyn清除的关键通路,也是αSyn相关神经毒性的直接靶点。啮齿类研究显示,增强LAMP2A可逆转神经变性,而LAMP2A缺陷会加速病理进展。为检验转化相关性,我们在非人灵长类中考察增加LAMP2A表达能否减轻注射帕金森病患者来源的路易体(LB)提取物所诱导的α-突触核蛋白病。增加LAMP2A表达保护黑质多巴胺能神经元免受LB诱导的αSyn神经变性,延迟病理相关αSyn物种的形成与释放,并对该灵长类模型的运动行为和认知功能产生有益影响。研究结果为增强CMA作为α-突触核蛋白病治疗策略提供了初步临床前证据。
Acta neuropathologica IF 10.3 2026-10-30 PMID: 42961519
A major challenge for identifying a disease-modifying cure for Parkinson's disease (PD) is creating models resembling key features of the disease including resting tremor, bradykinesia, muscle rigidity and gait disturbances. In addition, PD patients often develop cognitive symptoms that are associated with pathology in neocortical areas. Initially, PD rodent models were generated primarily by chemical neurotoxins that induce an acute loss of dopaminergic neurons. Upon discovery of familial-PD-linked genetic mutations in the SNCA gene-encoding α-synuclein (αS)-mice carrying these mutations provided deeper insight into the pathologic role of this synaptic protein throughout the brain. αS transgenic mouse models stand out for their ability to develop intraneuronal lesions that are rich in αS phospho-serine 129, a histopathological signature of the human PD brain. Recent advances in αS protein biochemistry led to the generation of mice carrying strategic amplifications of familial-PD-linked αS mutants, resulting in more pronounced neurodegeneration and progressive phenotype development. Here we review advances of αS transgenic mouse model development with a focus on strategic mutations that may have greater potential for identifying underlying disease mechanisms than classical single-mutant and wild-type αS overexpressing mice. We also present how the mice are currently used in testing drug efficacy and target engagement for PD drug discovery and outline strategies for utilizing such mice in basic and translational research.
中文摘要:寻找帕金森病(PD)疾病修饰性治愈手段的重大挑战在于建立能再现疾病关键特征的模型,这些特征包括静止性震颤、运动迟缓、肌强直和步态障碍。PD患者还常出现与大脑新皮质区病理相关的认知症状。早期PD啮齿类模型主要由化学神经毒素诱导,造成多巴胺能神经元急性丢失。随着在编码α-突触核蛋白(αS)的SNCA基因中发现家族性PD相关突变,携带这些突变的小鼠为理解该突触蛋白在全脑中的病理作用提供了更深认识。αS转基因小鼠模型的突出特点是可以形成富含αS磷酸化丝氨酸129的神经元内病变,该病理标志见于人PD脑。αS蛋白生物化学的近期进展促成了携带家族性PD相关αS突变体策略性扩增的小鼠,这类小鼠表现出更明显的神经变性和进行性表型发展。这里回顾αS转基因小鼠模型开发的进展,重点关注策略性突变;与经典单突变和野生型αS过表达小鼠相比,这些策略性突变可能更有助于识别潜在疾病机制。文章还介绍这些小鼠目前如何用于PD药物发现中的药效和靶点结合检测,并概述在基础与转化研究中利用此类小鼠的策略。
Nature neuroscience IF 20.3 2026-10-26 PMID: 42934350
The selective loss of dopaminergic neurons in the substantia nigra pars compacta is a defining feature of Parkinson's disease (PD), yet its underlying mechanisms remain unclear. NUS1, which encodes neurite outgrowth inhibitor-B receptor (NgBR), was recently identified as a PD risk gene. Here we show that NgBR is highly expressed in microglia, where its deficiency drives progressive PD-like motor deficits and dopaminergic neurodegeneration via the LCN2-SLC22A17 iron-transport axis in mice. NgBR deficiency in mouse and human microglia triggers endoplasmic reticulum stress and PERK-ATF4-NUPR1 signaling, which preferentially induces LCN2-mediated iron efflux over cytokine release. Subsequently, microglia-derived iron-loaded Holo-LCN2, but not iron-free Apo-LCN2, is internalized by SLC22A17, a receptor highly expressed in dopaminergic neurons, leading to iron overload and ferroptosis. Pharmacological inhibition of LCN2-SLC22A17 axis or ferroptosis alleviated dopaminergic neuron loss and PD-like symptoms caused by microglial NgBR deficiency in vitro and in vivo. Our findings identify disrupted intercellular iron homeostasis as a pathological driver of PD and highlight the LCN2-SLC22A17 axis as a potential therapeutic target.
中文摘要:黑质致密部多巴胺能神经元的选择性丢失是帕金森病(PD)的核心特征,但其机制尚不清楚。NUS1 编码神经突起生长抑制因子-B 受体(NgBR),近期被鉴定为 PD 风险基因。NgBR 在小胶质细胞中高表达,其缺失可通过小鼠 LCN2-SLC22A17 铁转运轴导致进行性 PD 样运动缺陷和多巴胺能神经退行性变。小鼠和人类小胶质细胞中 NgBR 缺失触发内质网应激和 PERK-ATF4-NUPR1 信号,优先诱导 LCN2 介导的铁外排而非细胞因子释放。随后,小胶质细胞来源的载铁 Holo-LCN2 而非无铁 Apo-LCN2 被多巴胺能神经元高表达的受体 SLC22A17 内化,引起铁过载和铁死亡。药理学抑制 LCN2-SLC22A17 轴或铁死亡可在体外和体内减轻小胶质细胞 NgBR 缺失所致多巴胺能神经元丢失和 PD 样症状。细胞间铁稳态紊乱因此被视为 PD 的病理驱动因素,LCN2-SLC22A17 轴则提示为潜在治疗靶点。
Signal transduction and targeted therapy IF 81.2 2026-10-26 PMID: 42928249
Parkinson's disease (PD) is clinically and biologically heterogeneous, and ethnic differences may influence its pathogenesis. However, single-nucleus transcriptomic data from East Asian populations remain limited. Here, we present a spatially resolved single-nucleus transcriptomic atlas of the human substantia nigra (SN) across the PD continuum, control, incidental Lewy body disease (iLBD), and advanced PD, in pathologically confirmed Korean individuals. Our integrative analysis revealed early α-synuclein aggregation in the ventrolateral SN, subtype-selective vulnerability of dopaminergic neurons, and relative preservation of the dorsomedial SN and ventral tegmental area. Trajectory and gene regulatory network analyses of astrocytes and microglia revealed spatiotemporally distinct, disease-associated glial responses, each driven by divergent molecular programs. We also identified two transcriptionally distinct vascular spatial clusters that exhibited differential vulnerability and remodeling. Spatial ligand-receptor analysis of α-synuclein-positive regions revealed intercellular signaling events associated with early pathology, including extracellular matrix remodeling and synaptic adhesion, which were prominent in the iLBD but largely diminished in advanced PD. Integration with PD genome-wide association studies using MAGMA demonstrated differential coupling between genetic risk, spatially resolved cell-state programs, and pseudotime-inferred microglial dynamics across ancestries. This study provides the first high-resolution, spatially mapped single-nucleus transcriptomic resource from an East Asian PD cohort, illuminating early perturbations in the midbrain intercellular and microenvironment that may underlie selective dopaminergic vulnerability and guide the development of ancestry-informed therapeutic strategies.
中文摘要:帕金森病在临床和生物学上具有异质性,族群差异可能影响其发病机制。东亚人群的单核转录组数据仍然有限。我们构建了来自病理确诊的韩国个体的、覆盖帕金森病连续谱(对照、偶发性路易体病和晚期帕金森病)的人黑质空间分辨单核转录组图谱。整合分析显示,腹外侧黑质存在早期α-突触核蛋白聚集,多巴胺能神经元呈亚型选择性脆弱,而背内侧黑质和腹侧被盖区相对保留。对星形胶质细胞和小胶质细胞的轨迹与基因调控网络分析显示,疾病相关胶质反应具有时空差异,并由不同分子程序驱动。我们还识别出两个转录上不同的血管空间簇,它们表现出不同的脆弱性和重塑。对α-突触核蛋白阳性区域的空间配体-受体分析显示,与早期病理相关的细胞间信号事件,包括细胞外基质重塑和突触黏附,这些事件在偶发性路易体病中突出,而在晚期帕金森病中大幅减弱。利用MAGMA与帕金森病全基因组关联研究整合,显示遗传风险、空间分辨细胞状态程序以及伪时间推断的小胶质细胞动态在不同祖先之间存在差异耦合。这一图谱提供了东亚帕金森病队列首个高分辨率、空间定位的单核转录组资源,揭示中脑细胞间和微环境的早期扰动,这些扰动可能构成选择性多巴胺能脆弱性的基础,并指导基于祖先信息的治疗策略开发。
ACS sensors IF 10.9 2026-10-24 PMID: 42921675
The ability to accurately quantify localized neuroinflammatory and neurodegenerative biomarkers in vivo is critical for enabling the early diagnosis of Parkinson's disease (PD). Here, we demonstrate a strategy for localized neuroinflammation quantification using an implantable glass-fiber-based CRISPR/Cas immunosensor. When interfaced with a portable fluorescence detector, our platform enables the spatially resolved multiplex detection of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and alpha-synuclein (α-syn) in the PD rat brain. The sensor surface was modified with functionalized liquid metal nanoparticles to enable antibody immobilization and long-term in vivo operation. This method demonstrated high specificity, excellent linearity in artificial cerebrospinal fluid (R2 > 0.91), sustained surface stability over 28 days, good biocompatibility with PC12 cells, and selective antibacterial activity against Staphylococcus aureus. Following cannula implantation into the substantia nigra pars compacta (SNc) of a 6-hydroxydopamine-induced PD rat model, the functionalized glass fiber enabled repeated, minimally invasive biomarker sampling at 6, 12, and 24 h postimplantation. Systemic inflammation induced by lipopolysaccharide (LPS) triggered marked elevations in TNF-α, IL-6, and α-syn, peaking at 6 h post-LPS. This implantable fiber-based biosensing method offers a promising reliable approach for early PD diagnosis, disease progression tracking, and investigation of neuroimmune interactions in neurodegenerative diseases in a point-of-care scenario.
中文摘要:在体内准确定量局部神经炎症和神经退行性生物标志物,对实现帕金森病(PD)的早期诊断至关重要。在此展示一种利用可植入玻璃纤维的CRISPR/Cas免疫传感器进行局部神经炎症定量的策略。该平台与便携式荧光检测器连接后,可在PD大鼠脑内对肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和α-突触核蛋白(α-syn)进行空间分辨的多重检测。传感器表面经功能化液态金属纳米颗粒修饰,以实现抗体固定和长期体内运行。该方法表现出高特异性,在人工脑脊液中具有良好线性(R2 > 0.91),表面稳定性持续28天,对PC12细胞具有良好生物相容性,并对金黄色葡萄球菌具有选择性抗菌活性。将套管植入6-羟基多巴胺诱导的PD大鼠模型黑质致密部(SNc)后,功能化玻璃纤维可在植入后6、12和24小时进行重复、微创的生物标志物采样。脂多糖(LPS)诱导的系统性炎症引发TNF-α、IL-6和α-syn显著升高,并在LPS后6小时达到峰值。这种可植入纤维生物传感方法为早期PD诊断、疾病进展追踪以及在即时检测场景中研究神经退行性疾病中的神经免疫相互作用提供了一种有前景的可靠途径。

4癫痫 (3篇)

临床研究 (1篇)

Molecular psychiatry IF 10.4 2026-10-30 PMID: 42963370
PCDH19-clustering epilepsy (PCDH19-CE) is an infantile-onset neurodevelopmental disorder characterised by clusters of seizures, typically triggered by fever. PCDH19-CE follows an unusual X-linked inheritance pattern whereby heterozygous females, and males with X-chromosome disomy or pathogenic postzygotic mosaic PCDH19 variants, are affected, while hemizygous males are spared. We aggregate published PCDH19 variants and their corresponding PCDH19-CE phenotypes to analyse phenotype-genotype correlations. Data extracted from 110 publications identified 689/735 (94%) individuals with PCDH19 variants and the typical PCDH19-CE phenotype. Three hundred seventy-three unique PCDH19 variants were identified; 195 were not recorded in ClinVar. Seizure onset prior to 12 months of age was associated with more severe intellectual disability (p < 0.001) and the presence of psychiatric morbidity (p = 0.001). There were no phenotypic differences between missense, nonsense, and frameshift variants or between individuals of different geographical backgrounds, which was assessed as a proxy for ancestry. Twenty-nine hemizygous males with constitutive PCDH19 variants did not exhibit the typical PCDH19-CE phenotype, suggesting that the identification of variants in these individuals likely results from chance or ascertainment bias. The correlation between earlier seizure onset and poorer neurodevelopmental outcomes emphasises a critical window for therapeutic intervention. The lack of phenotypic difference between variant types demonstrates that loss of PCDH19 function underpins PCDH19-CE. Moreover, the identification of PCDH19 cytoplasmic domain variants in 78 affected individuals challenges the traditional view that PCDH19-CE is caused primarily by defects in cell-cell adhesion, as variants in this domain are expected to disrupt the nuclear function(s) of PCDH19.
中文摘要:PCDH19簇集性癫痫(PCDH19-CE)是一种婴儿期起病的神经发育障碍,特征是癫痫发作簇集,常由发热触发。PCDH19-CE遵循不寻常的X连锁遗传模式:杂合女性以及X染色体二体或携带致病性合子后嵌合PCDH19变异的男性受累,半合子男性不受累。研究汇总已发表的PCDH19变异及其对应的PCDH19-CE表型,分析表型与基因型的相关性。从110篇文献提取的数据共识别出689/735例(94%)携带PCDH19变异且具有典型PCDH19-CE表型的个体。共发现373个独特PCDH19变异,其中195个未收录于ClinVar。12月龄前起病与更严重的智力障碍(p<0.001)及存在精神疾病共病(p=0.001)相关。错义、无义和移码变异之间未见表型差异,不同地域背景个体之间(作为祖源替代指标评估)也未见表型差异。29例携带构成性PCDH19变异的半合子男性未表现出典型PCDH19-CE表型,提示在这些个体中发现变异可能源于偶然或 ascertainment bias。更早起病与更差神经发育结局之间的相关性强调治疗干预存在关键窗口。不同变异类型之间缺乏表型差异表明PCDH19功能丧失是PCDH19-CE的基础。78例受累个体中识别出PCDH19胞质结构域变异,这挑战了PCDH19-CE主要由细胞间黏附缺陷所致的传统观点,因为该结构域变异预期会破坏PCDH19的核功能。

基础研究 (2篇)

Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957748
Epilepsy is increasingly viewed as a systemic disorder in which recurrent seizures intersect with vascular, autonomic, respiratory, and cardiac processes to influence cardiovascular vulnerability. Seizure-related neuroinflammation involves multiple interacting mediator pathways, including HMGB1/TLR4-RAGE signaling, inflammasome/IL-1β activation, IL-6/IL-6R-gp130 signaling, albumin/TGF-β signaling following blood-brain barrier (BBB) disruption, and tumor necrosis factor-alpha (TNF-α)/TNF receptor (TNFR) signaling. Within this inflammatory network, TNF/TNFR signaling represents a mechanistically distinct and translationally relevant framework for examining how immune activation intersects with endothelial-barrier dysfunction, neurovascular unit injury, autonomic disturbance, inflammatory communication across neural and cardiovascular compartments, and cardiac vulnerability. This review integrates direct evidence from epilepsy studies with mechanistic insights from related experimental studies of BBB injury, myocardial ischemia-reperfusion injury, cardioprotection, and brain-heart communication. TNF biology is determined by ligand form, receptor subtype, cellular compartment, and disease context. Soluble TNF preferentially engages TNFR1-associated inflammatory and injury-amplifying pathways, whereas transmembrane TNF/TNFR2 signaling may support regulatory or reparative responses in selected settings. In epilepsy, seizure-associated inflammation, BBB dysfunction, glial activation, and autonomic imbalance may interact to increase susceptibility to arrhythmogenic stress, myocardial injury, adverse cardiac remodeling, and cardiorespiratory instability relevant to sudden unexpected death in epilepsy (SUDEP). However, epilepsy-specific evidence directly linking TNF/TNFR signaling to cardiovascular outcomes remains limited, and many mechanistic connections currently rely on converging evidence from neurovascular and cardiovascular research. Future studies should integrate compartment-resolved inflammatory profiling with autonomic, respiratory, electrocardiographic, and cardiac phenotyping to distinguish inflammatory signatures of disease severity from modifiable contributors to cardiovascular risk. Such approaches may enable phenotype-specific strategies to better understand and ultimately mitigate the brain-heart consequences of epilepsy.
中文摘要:癫痫日益被视为一种系统性疾病,反复发作的癫痫发作与血管、自主神经、呼吸及心脏过程相互交织,影响心血管易感性。癫痫发作相关神经炎症涉及多条相互作用的介质通路,包括HMGB1/TLR4-RAGE信号、炎症小体/IL-1β激活、IL-6/IL-6R-gp130信号、血脑屏障(BBB)破坏后的白蛋白/TGF-β信号,以及肿瘤坏死因子-α(TNF-α)/TNF受体(TNFR)信号。在这一炎症网络中,TNF/TNFR信号提供了一个机制上独特且具有转化相关性的框架,用于考察免疫激活如何与内皮屏障功能障碍、神经血管单元损伤、自主神经紊乱、神经与心血管分区之间的炎症通讯以及心脏易感性相交汇。该综述将癫痫研究的直接证据与BBB损伤、心肌缺血-再灌注损伤、心脏保护及脑-心通讯等相关实验研究的机制认识相结合。TNF生物学由配体形式、受体亚型、细胞分区和疾病背景决定。可溶性TNF优先激活与TNFR1相关的炎症和损伤放大通路,而跨膜型TNF/TNFR2信号在特定情形下可能支持调节性或修复性反应。在癫痫中,发作相关炎症、BBB功能障碍、胶质细胞激活和自主神经失衡可能相互作用,增加对致心律失常应激、心肌损伤、不良心脏重构及与癫痫猝死(SUDEP)相关的心肺不稳定的易感性。然而,直接将TNF/TNFR信号与心血管结局联系起来的癫痫特异性证据仍然有限,许多机制联系目前依赖神经血管和心血管研究的汇聚证据。未来研究应将分区解析的炎症谱分析与自主神经、呼吸、心电图和心脏表型评估整合起来,以区分疾病严重程度的炎症特征与心血管风险的可调控贡献因素。这类方法可能促成表型特异性策略,以更好地理解并最终减轻癫痫的脑-心后果。
Pharmacological research IF 12.2 2026-10-25 PMID: 42927808
Despite the efficacy of current antiseizure medications in managing seizures, approximately one-third of patients develop refractory epilepsy, highlighting an urgent need to uncover the molecular mechanisms driving epileptogenesis. This process emerges from a complex interplay of molecular alterations, involving changes in neuronal signaling pathways. Among these, brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, the full-length tropomyosin receptor kinase B (TrkB-FL), are heavily implicated in epilepsy pathophysiology. While traditionally recognized for promoting synaptic plasticity, BDNF signaling can become maladaptive in pathological states. Consequently, BDNF exhibits a paradoxical dual role in epilepsy, acting as a proepileptogenic factor in the acute phase, while exerting antiepileptic effects during the chronic phase. Recently, a calpain-dependent proteolytic mechanism mediating TrkB-FL cleavage, previously described in Alzheimer's disease (AD) and cerebral ischemia, has been shown to occur during epileptogenesis. Elevated levels of the intracellular cleavage product of TrkB-FL, TrkB-ICD, have been observed in the hippocampus of patients with refractory epilepsy, establishing its clinical relevance. In vitro, TrkB-ICD overexpression depolarizes neuronal membranes, increases miniature excitatory postsynaptic current frequency, and alters the transcription of genes related to synaptic transmission and plasticity. In vivo, its overexpression induces long-term memory impairment, a common comorbidity in epilepsy. Moreover, in experimental epilepsy models, TrkB-ICD protein levels correlate with seizure frequency during the acute phase (status epilepticus) and remain elevated during the chronic phase (established epilepsy). These findings highlight TrkB-FL cleavage and TrkB-ICD formation as molecular determinants in epileptogenesis, providing a biological rationale for the contrasting effects of BDNF. Inhibiting this cleavage, using tools like cell-penetrating peptides, represents a promising therapeutic avenue. As the field moves forward, elucidating the precise functions, regulation, and translational potential of the TrkB-FL proteolysis and TrkB-ICD formation may yield innovative, disease-modifying strategies for epilepsy, moving beyond the symptomatic suppression offered by conventional antiseizure drugs.
中文摘要:现有抗癫痫发作药物虽能控制癫痫发作,但约三分之一患者仍发展为耐药性癫痫,这凸显出阐明致痫分子机制的紧迫性。致痫过程源于分子改变的复杂交互,涉及神经元信号通路的变化。其中,脑源性神经营养因子(BDNF)及其高亲和力受体——全长原肌球蛋白受体激酶B(TrkB-FL)与癫痫病理生理密切相关。BDNF信号传统上被认为促进突触可塑性,但在病理状态下可转为适应不良。因此BDNF在癫痫中呈现矛盾的双重作用:急性期起促癫痫发生作用,慢性期则发挥抗癫痫效应。近期研究显示,一种由钙蛋白酶依赖的蛋白水解机制介导的TrkB-FL剪切,此前已在阿尔茨海默病和脑缺血中报道,同样发生于致痫过程中。在耐药性癫痫患者海马中可观察到TrkB-FL的胞内剪切产物TrkB-ICD水平升高,确立了其临床相关性。体外实验中,TrkB-ICD过表达可使神经元膜去极化、增加微小兴奋性突触后电流频率,并改变与突触传递和可塑性相关基因的转录。体内实验中,其过表达可诱导长期记忆损害,而这是癫痫常见的共病。此外,在实验性癫痫模型中,TrkB-ICD蛋白水平在急性期(癫痫持续状态)与发作频率相关,并在慢性期(已成型的癫痫)持续升高。这些发现表明TrkB-FL剪切及TrkB-ICD形成是致痫过程的分子决定因素,为BDNF的双向效应提供了生物学解释。以细胞穿膜肽等工具抑制该剪切过程,是一条有前景的治疗途径。随着研究推进,阐明TrkB-FL蛋白水解与TrkB-ICD形成的精确功能、调控方式及转化潜力,可能带来创新的疾病修饰策略,超越传统抗癫痫药物仅能对症抑制发作的局限。

5神经肌肉病与周围神经 (3篇)

基础研究 (3篇)

Science advances IF 13.9 2026-10-30 PMID: 42962021
Diabetic peripheral neuropathy (DPN) affects up to half of people with diabetes and lacks disease-modifying therapy. Here, we profiled MSC-EV biodistribution and multiomic programs across diabetic models, with key nerve repair established in db/db mice and corroborated in high-fat diet/streptozotocin- and methionine-choline-deficient mice. Systemically administered EVs predominantly accumulated in the liver and improved peripheral nerve structure and function, with benefits supported by glycemia-controlled or glycemia-adjusted analyses rather than being fully explained by systemic glycemic changes. EV treatment was associated with reduced circulating injury markers, attenuated spinal inflammatory responses, and improved endothelial junction integrity. Mechanistically, EV-encapsulated miR-24-3p repressed hepatic CD74, coinciding with reduced MHC II/NF-κB activity in macrophages. Hepatic CD74 overexpression promoted systemic inflammation and peripheral nerve injury, whereas pharmacologic NF-κB inhibition recapitulated EV-associated benefits. Together, these data define a liver-to-nerve causal axis and support EV-mediated restraint of hepatic CD74-NF-κB signaling as a cross-organ strategy for DPN repair.
中文摘要:糖尿病周围神经病变(DPN)影响多达一半的糖尿病患者,缺乏改善疾病的治疗。我们在多种糖尿病模型中分析了MSC-EV的生物分布和多组学程序,在db/db小鼠中确立了关键神经修复作用,并在高脂饮食/链脲佐菌素及甲硫氨酸-胆碱缺乏小鼠中得到印证。全身给药的EV主要蓄积于肝脏,改善周围神经结构与功能;血糖控制或血糖校正分析支持这些获益,并非完全由全身血糖变化解释。EV治疗与循环损伤标志物降低、脊髓炎症反应减轻及内皮连接完整性改善相关。机制上,EV包裹的miR-24-3p抑制肝脏CD74,伴随巨噬细胞MHC II/NF-κB活性降低。肝脏CD74过表达促进全身炎症和周围神经损伤,而药理性NF-κB抑制重现了EV相关获益。这些数据界定了一条肝到神经的因果轴,并支持EV介导的肝脏CD74-NF-κB信号抑制作为DPN修复的跨器官策略。
Pharmacological research IF 12.2 2026-10-28 PMID: 42951120
Paclitaxel-induced peripheral neuropathy (PIPN) is a dose-limiting complication of cancer chemotherapy driven by macrophage-mediated NLRP3 inflammasome activation. While suppressing TLR-NF-κB-dependent priming can limit neuroinflammation by reducing both NLRP3 induction and downstream inflammasome activation, such upstream intervention may also affect broader immune transcriptional programs in vulnerable oncology patients. Here, we identify a structural division of labor within histone deacetylase 6 (HDAC6) that pharmacologically uncouples the priming and assembly steps of NLRP3 activation. In a murine PIPN model, we demonstrate that paclitaxel directly primes macrophages. Complementary ND7/23-BMDM experiments support a model in which ATP released from paclitaxel-stressed neuronal cells provides a second signal for inflammasome assembly. By integrating domain-selective pharmacology with genetic knockdown-rescue using catalytically inactive and ZnF-UBP-deletion mutants, we reveal that the catalytic domain of HDAC6 governs upstream TLR4-NF-κB-dependent priming. In contrast, the non-catalytic ZnF-UBP domain is required for downstream HDAC6-NLRP3-ASC complexation and ASC speck assembly, ultimately driving caspase-1 activation, GSDMD cleavage, and IL-1β release. In vivo, targeting the ZnF-UBP domain with CP31 effectively alleviated paclitaxel-evoked pain hypersensitivity and dorsal root ganglion (DRG) neuroinflammation without altering canonical α-tubulin acetylation. By reframing HDAC6 into domain-separable intervention points, we provide a pathway-restricted therapeutic strategy for PIPN that precisely disarms downstream pathological inflammasome assembly while largely preserving the measured upstream priming responses.
中文摘要:紫杉醇诱导的周围神经病变(PIPN)是癌症化疗的剂量限制性并发症,由巨噬细胞介导的NLRP3炎症小体激活驱动。抑制TLR-NF-κB依赖的启动步骤可通过减少NLRP3诱导及下游炎症小体激活来限制神经炎症,但此类上游干预也可能影响脆弱肿瘤患者更广泛的免疫转录程序。本研究识别出组蛋白去乙酰化酶6(HDAC6)内部的结构性分工,可在药理学上解耦NLRP3激活的启动与组装步骤。在小鼠PIPN模型中,紫杉醇直接启动巨噬细胞。ND7/23-BMDM互补实验支持如下模型:紫杉醇应激的神经元细胞释放的ATP提供炎症小体组装的第二信号。通过将结构域选择性药理学与使用催化失活及ZnF-UBP缺失突变体的基因敲低-回补相结合,我们发现HDAC6催化结构域调控上游TLR4-NF-κB依赖的启动。相反,非催化性ZnF-UBP结构域是下游HDAC6-NLRP3-ASC复合物形成及ASC斑点组装所必需,并最终驱动caspase-1激活、GSDMD切割和IL-1β释放。在体内,用CP31靶向ZnF-UBP结构域可有效缓解紫杉醇诱发的痛觉过敏和背根神经节(DRG)神经炎症,而不改变经典α-微管蛋白乙酰化。通过将HDAC6重新界定为结构域可分离的干预点,我们为PIPN提供了一种通路受限的治疗策略,可精确解除下游病理性炎症小体组装,同时大体保留所测的上游启动反应。
Archives of toxicology IF 10.9 2026-10-24 PMID: 42925314
Neuropathy target esterase (NTE), localized predominantly to the endoplasmic reticulum, is highly expressed within the nervous system. Under physiological conditions, NTE functions mainly as a phospholipase B/lysophospholipase involved in phosphatidylcholine and lysophosphatidylcholine turnover, thereby maintaining phospholipid homeostasis, membrane integrity, and axonal stability. In toxicology, NTE is of particular interest as the principal molecular target in organophosphorus-induced delayed neurotoxicity (OPIDN), a syndrome that develops days to weeks after exposure to certain organophosphorus (OP) compounds. Unlike acute cholinergic toxicity caused by acetylcholinesterase inhibition, OPIDN is initiated by inhibition of NTE followed by "aging" of the enzyme-inhibitor complex, an essentially irreversible process considered critical for neuropathic outcome. The resulting loss of NTE activity disrupts phospholipid metabolism, promotes lysophospholipid accumulation, endoplasmic reticulum stress, calcium dyshomeostasis, and cytoskeletal breakdown, leading to distal axon degeneration in both the central and peripheral nervous systems. Clinically, OPIDN manifests after a latent phase with progressive weakness, sensory abnormalities, gait impairment, and in severe cases persistent spasticity or paralysis. This review summarizes the current knowledge on NTE structure, catalytic function, tissue distribution, and physiological significance, and integrates these findings with the molecular and clinical features of OPIDN. Particular attention is paid to the distinction between aging (neuropathic) and non-aging (non-neuropathic) NTE inhibitors, the structural determinants of neuropathic potential, and its clinical implications.
中文摘要:神经病靶酯酶(NTE)主要定位于内质网,在神经系统中高表达。生理条件下,NTE主要作为磷脂酶B/溶血磷脂酶参与磷脂酰胆碱和溶血磷脂酰胆碱的周转,从而维持磷脂稳态、膜完整性和轴突稳定性。在毒理学中,NTE因作为有机磷诱导的迟发性神经毒性(OPIDN)的主要分子靶点而受到关注;该综合征在接触某些有机磷化合物后数天至数周出现。与乙酰胆碱酯酶抑制所致的急性胆碱能毒性不同,OPIDN由NTE抑制及酶-抑制剂复合物「老化」启动,这一过程基本不可逆,被认为是神经病性结局的关键。NTE活性丧失扰乱磷脂代谢,促进溶血磷脂蓄积、内质网应激、钙稳态失衡和细胞骨架崩解,导致中枢和外周神经系统远端轴突变性。临床上,OPIDN经潜伏期后表现为进行性无力、感觉异常、步态障碍,严重者出现持续性痉挛或瘫痪。本综述总结NTE结构、催化功能、组织分布和生理意义的最新认识,并将这些发现与OPIDN的分子和临床特征整合。特别关注老化型(神经病性)与非老化型(非神经病性)NTE抑制剂的区别、神经病性潜能的结构决定因素及其临床意义。

6多发性硬化与神经免疫 (2篇)

临床研究 (1篇)

EBioMedicine IF 11.2 2026-10-29 PMID: 42956540
The 2024 McDonald criteria broaden the definition of multiple sclerosis (MS), enabling diagnosis in individuals with asymptomatic MRI findings or clinical presentations not meeting the 2017 criteria. We assessed whether these criteria identify such cases using independent laboratory/imaging biomarkers and whether these biomarkers predict subsequent disease activity. Participants with asymptomatic MRI findings or clinical presentations not meeting the 2017 criteria were included and stratified according to the 2024 criteria. Serum neurofilament light chain (sNfL) and 3T brain MRI measures-including normalised brain volumes, T2 lesion load (T2LL), cortical lesion (CL) and paramagnetic rim lesion (PRL)-were compared between McDonald2024-positive and McDonald2024-negative groups, and with age/sex matched McDonald2017-positive cases according to the 2017 criteria; predictors of disease activity were assessed using penalised-Cox regression. A total of 141 participants were included: 95 not meeting the 2017 criteria (n = 64 asymptomatic MRI findings; n = 31 clinical presentations), stratified as McDonald2024-positive (n = 46) or McDonald2024-negative (n = 49), and 46 McDonald2017-positive cases. McDonald2024-positive vs. McDonald2024-negative cases showed higher age-corrected sNfL Z-scores (median 0.28[IQR 0.76] vs. -0.12[0.82], p = 0.003/pFDR = 0.006), reduced normalised thalamic volume (mean 0.009±[SD]0.0007 vs. 0.010 ± 0.0007, p = 0.003/pFDR = 0.006), and higher CL (1[4] vs. 0[0], p < 0.001/pFDR < 0.001) and PRL (1[1] vs. 0[0], p < 0.001/pFDR = 0.003) counts (differences remaining significant after age/sex, disease duration and T2LL adjustments). Biomarker profiles were comparable between McDonald2024-positive and McDonald2017-positive cases. Penalised-Cox regression (n = 52) identified sNfL Z-score and PRL presence as the most consistently selected predictors of disease activity, with higher bootstrap stability for sNfL (0.84) than PRL (0.76), and good model discrimination (C-index = 0.71). The 2024 McDonald criteria identify individuals not meeting the 2017 criteria who already exhibit MS-like neuroinflammatory/neurodegenerative pathological changes. These are reflected by laboratory and imaging biomarkers, including sNfL, which may predict subsequent disease activity and complement current diagnostic frameworks to support early clinical decision-making. King Baudouin Foundation; Cliniques Universitaires Saint-Luc; Fondation Charcot Stichting; Fund for Scientific Research (FNRS); ECTRIMS; Biogen; Sanofi.
中文摘要:2024年McDonald标准拓宽了多发性硬化(MS)的定义,使具有无症状MRI表现或不符合2017标准临床表现的个体也可被诊断。我们采用独立实验室/影像生物标志物评估这些标准能否识别此类病例,并评估这些标志物是否预测后续疾病活动。纳入具有无症状MRI表现或不符合2017标准临床表现的参与者,并按2024标准分层。比较McDonald2024阳性组与阴性组之间,以及与按2017标准年龄/性别匹配的McDonald2017阳性病例之间的血清神经丝轻链(sNfL)和3T脑MRI指标,包括标准化脑体积、T2病灶负荷(T2LL)、皮质病灶(CL)和顺磁边缘病灶(PRL);采用惩罚Cox回归评估疾病活动预测因素。共纳入141名参与者:95名不符合2017标准者(n=64无症状MRI表现;n=31临床表现),分层为McDonald2024阳性(n=46)或McDonald2024阴性(n=49),以及46例McDonald2017阳性病例。McDonald2024阳性与阴性病例相比,年龄校正sNfL Z评分更高(中位数0.28[IQR 0.76] vs -0.12[0.82],p=0.003/pFDR=0.006),标准化丘脑体积降低(均值0.009±[SD]0.0007 vs 0.010±0.0007,p=0.003/pFDR=0.006),CL计数更高(1[4] vs 0[0],p<0.001/pFDR<0.001)和PRL计数更高(1[1] vs 0[0],p<0.001/pFDR=0.003)(调整年龄/性别、疾病病程和T2LL后差异仍显著)。McDonald2024阳性与McDonald2017阳性病例的生物标志物特征相当。惩罚Cox回归(n=52)确定sNfL Z评分和PRL存在是疾病活动最一致被选择的预测因素,sNfL的bootstrap稳定性(0.84)高于PRL(0.76),模型区分度良好(C-index=0.71)。2024年McDonald标准识别出不符合2017标准但已表现出MS样神经炎症/神经退行性病理改变的个体。这些改变由实验室和影像生物标志物反映,包括sNfL,其可能预测后续疾病活动,并补充当前诊断框架以支持早期临床决策。资助:国王博杜安基金会;圣吕克大学诊所;Charcot Stichting基金会;科学研究基金(FNRS);ECTRIMS;Biogen;Sanofi。

基础研究 (1篇)

ACS nano IF 17.3 2026-10-27 PMID: 42937574
Pericyte dysfunction triggers blood-brain barrier (BBB) disruption and subsequent aberrant immune infiltration in multiple sclerosis (MS), yet targeted interventions remain lacking. Here, we engineered a dual-functional fusion peptide (VLC) for pericyte targeting and therapeutic intervention and subsequently conjugated it with luteolin to construct a peptide-drug conjugate (PDC)-based ROS-responsive nanoprodrug (VLC@Lut-NPs). This system significantly suppressed MMP-9 overactivation and mitigated neuroinflammation. To optimize the pharmacokinetic profile of the PDC nanotherapeutic, we adopted subcutaneous administration, achieving a prolonged circulation half-life and enhancing brain drug accumulation (AUCbrain) by 2.65-fold compared with intravenous injection. In two MS models, VLC@Lut-NPs restored pericyte homeostasis, reinforced BBB integrity, attenuated aberrant peripheral immune infiltration, and ultimately promoted myelin repair and regeneration. Notably, a once-every-other-day subcutaneous regimen outperformed daily intravenous administration. By bridging peripheral immunity and the neurovascular unit, this work identifies pericytes as a central regulatory node and establishes a pericyte-targeted PDC nanoplatform for durable MS treatment, highlighting its translational potential as a complementary strategy to conventional immunomodulatory approaches.
中文摘要:周细胞功能障碍可触发血脑屏障破坏,并引起多发性硬化中的异常免疫浸润,但针对这一环节的干预手段仍然缺乏。研究构建了用于周细胞靶向和治疗干预的双功能融合肽VLC,并将其与木犀草素偶联,制备了基于肽-药物偶联物的ROS响应型纳米前药VLC@Lut-NPs。该系统显著抑制MMP-9过度活化,减轻神经炎症。为优化该肽-药物偶联物纳米治疗药物的药代动力学特征,研究采用皮下给药,使循环半衰期延长,并使脑内药物累积的AUC较静脉注射提高2.65倍。在两种多发性硬化模型中,VLC@Lut-NPs恢复周细胞稳态,增强血脑屏障完整性,减轻异常外周免疫浸润,并最终促进髓鞘修复与再生。隔日一次皮下给药方案优于每日静脉给药。该工作连接外周免疫与神经血管单元,将周细胞确定为中枢调控节点,并建立了靶向周细胞的肽-药物偶联物纳米平台,用于持久治疗多发性硬化,显示其作为传统免疫调节策略补充方案的转化潜力。

7神经重症与脑损伤 (2篇)

基础研究 (2篇)

Intensive care medicine IF 22.0 2026-10-29 PMID: 42955320
Ventilator-associated pneumonia (VAP) is frequent after traumatic brain injury (TBI), but its biological meaning and outcome impact remain incompletely defined. Traditional models emphasise mechanical ventilation, aspiration, colonisation, endotracheal tube biofilm, and hospital pathogens. These mechanisms remain essential, but they do not fully explain the early clustering, heterogeneous susceptibility, changing bacteriology, and variable mortality effect observed after TBI. Severe brain injury creates an early vulnerable host state through impaired consciousness and airway protection, neuroimmune dysregulation, autonomic and endocrine activation, altered pulmonary immune surveillance, and, in many patients, extracranial trauma, shock, transfusion, or thoracic injury. These processes interact with ventilation, antibiotic pressure, and rapid respiratory microbiome disruption. Early VAP may reflect abrupt loss of control after injury and intubation, whereas late VAP may reflect persistent or secondary failure driven by biofilm maturation, antibiotic selection, multidrug-resistant pathogens, and intensive care unit (ICU)-acquired immune dysfunction. Clinically, VAP consistently prolongs ventilation, ICU stay, antibiotic exposure, and resource use, while its independent effect on mortality is phenotype- and context-dependent. This model proposes a timing-sensitive ecological framework in which established mechanisms may converge early and with particular clinical intensity after severe TBI, creating a vulnerable host-microbe state that may lower the threshold for clinically apparent infection. Future studies should distinguish isolated TBI from polytrauma, compare TBI with other acute brain injuries and non-neurological ventilated populations, and incorporate dynamic immune, microbial, and trajectory-based outcomes. VAP after TBI should be viewed as a timing-sensitive interaction between ventilator exposure and early host vulnerability, not as a distinct disease entity or as a pneumonia pathway unique to traumatic brain injury. The TBI-focused contribution lies in the early convergence of otherwise non-unique mechanisms: impaired airway control, aspiration risk, neuroimmune-endocrine activation, treatment exposure, dysbiosis, and extracranial injury burden, rather than in any single TBI-specific mechanism. Isolated TBI and TBI with polytrauma are biologically different phenotypes and should be separated in future studies. Early and late VAP may represent different phases of loss of pulmonary host-microbe containment; this distinction is probabilistic rather than TBI-specific in itself and requires validation in TBI-stratified cohorts. Mortality remains clinically relevant but context-dependent; VAP more consistently modifies recovery trajectory, ventilator dependence, ICU stay, antibiotic exposure, and possibly neurological recovery.
中文摘要:呼吸机相关性肺炎(VAP)在创伤性脑损伤(TBI)后常见,但其生物学意义和对结局的影响仍未完全明确。传统模型强调机械通气、误吸、定植、气管导管生物膜和医院病原体。这些机制仍然重要,却不能完全解释TBI后观察到的早期聚集、易感性异质、细菌学变化和死亡效应不一。严重脑损伤通过意识障碍和气道保护受损、神经免疫失调、自主神经和内分泌激活、肺免疫监视改变,以及许多患者存在的颅外创伤、休克、输血或胸部损伤,形成早期易感宿主状态。这些过程与通气、抗生素压力和呼吸道微生物组快速破坏相互作用。早期VAP可能反映损伤和插管后控制突然丧失,晚期VAP可能反映生物膜成熟、抗生素选择、多重耐药病原体和重症监护病房(ICU)获得性免疫功能障碍驱动的持续或继发性失败。临床上,VAP一致延长通气、ICU停留、抗生素暴露和资源使用,而其独立死亡效应取决于表型和背景。该模型提出时间敏感的生态框架:既有机制在严重TBI后可能早期汇聚并具有特殊临床强度,形成易感宿主-微生物状态,可能降低临床明显感染的阈值。未来研究应区分孤立性TBI与多发伤,比较TBI与其他急性脑损伤及非神经性通气人群,并纳入动态免疫、微生物和基于轨迹的结局。TBI后VAP应视为通气暴露与早期宿主易感性之间的时间敏感相互作用,而非独立疾病实体或TBI特有的肺炎通路。以TBI为重点的贡献在于本来并非独特的机制早期汇聚:气道控制受损、误吸风险、神经免疫-内分泌激活、治疗暴露、菌群失调和颅外损伤负担,而不是任何单一TBI特异性机制。孤立性TBI与TBI伴多发伤是生物学不同的表型,未来研究应将其分开。早期和晚期VAP可能代表肺宿主-微生物控制丧失的不同阶段;这种区分本身是概率性的,并非TBI特异性,需要在TBI分层队列中验证。死亡结局仍有临床相关性,但依赖背景;VAP更一致地改变恢复轨迹、呼吸机依赖、ICU停留、抗生素暴露,并可能影响神经恢复。
Advanced healthcare materials IF 11.0 2026-10-28 PMID: 42949814
Electrical stimulation (ES) offers a robust approach to boost the efficacy of stem cell transplantation therapy for the treatment of neurological disorders. Notably, wireless technology blends convenience with the elimination of infection risk posed by wired connections, but the challenge lies in the integration of wireless-enabled stimulation materials and stem cell carriers. Here, we describe a flexible annular conductive dopamine-modified hyaluronic acid (HAD)/polyvinyl alcohol (PVA)/carbon nanotube‌ (CNT) hydrogel that acts as a secondary coil to realize wireless ES via electromagnetic induction, while also serving as a three-dimensional (3D) scaffold carrier for endogenous neural stem cells (NSCs). Established on the annular HAD/PVA/CNT hydrogel with high conductivity and good biocompatibility, wireless ES significantly enhances neuronal differentiation of NSCs. Furthermore, transplantation of the NSC-laden annular hydrogel into a traumatic brain injury (TBI) rat model modulates the behaviors of both exogenous and endogenous neural cells. The combined therapy of wireless ES and NSC transplantation promotes neuronal differentiation in both the injury zone and hippocampus in association with the PI3K-Akt pathway, reduces post-traumatic inflammatory responses, and effectively restores motor and memory functions in TBI rats. This study offers a promising therapeutic strategy of integrating wireless ES with stem cell transplantation therapy for brain injury repair.
中文摘要:电刺激(ES)可增强干细胞移植治疗神经系统疾病的效果。无线技术兼具便利性并消除有线连接带来的感染风险,但将无线刺激材料与干细胞载体整合仍具挑战。我们构建了一种柔性环形导电多巴胺修饰透明质酸(HAD)/聚乙烯醇(PVA)/碳纳米管(CNT)水凝胶,其作为次级线圈通过电磁感应实现无线ES,同时作为内源性神经干细胞(NSCs)的三维(3D)支架载体。基于具有高导电性和良好生物相容性的环形HAD/PVA/CNT水凝胶,无线ES显著促进NSCs向神经元分化。将负载NSCs的环形水凝胶移植到创伤性脑损伤(TBI)大鼠模型后,可调控外源性和内源性神经细胞的行为。无线ES与NSC移植联合治疗与PI3K-Akt通路相关地促进损伤区及海马内的神经元分化,减轻创伤后炎症反应,并有效恢复TBI大鼠的运动和记忆功能。该研究为整合无线ES与干细胞移植治疗促进脑损伤修复提供了有前景的治疗策略。

8神经遗传/影像与基础转化 (2篇)

临床研究 (1篇)

JAMA neurology IF 23.6 2026-10-26 PMID: 42931738
Leukoencephalopathies are clinically and etiologically heterogeneous disorders, and establishing a specific diagnosis remains challenging. Patients with unexplained spastic paraplegia and brain white matter hyperintensities (WMH) may be misdiagnosed as having multiple sclerosis, potentially exposing them to unnecessary immunosuppressive therapy. To define the clinical, radiological, and genetic features of spinal predominant demyelinating leukodystrophy with leg spasticity (SPDMLS). This case series involved participants from 4 tertiary referral hospitals within the China Alliance for Rare Diseases during the period July 2019 to August 2025. The study design integrated clinical evaluations and whole-exome sequencing (WES), as well as targeted plasma lipidomics correlated with SPATAX-EUROSPA disability stages. Variant pathogenicity was evaluated using an oligodendrocyte-specific knock-in mouse model. Participants were patients with unexplained spastic paraplegia and central nervous system (CNS) WMH and available family members, including presymptomatic carriers. WES, genetic characterization, testing. Identification of disease-associated gene and characterization of clinical, radiological, and genetic features of SPDMLS. Twenty-six individuals from 11 unrelated families were included; 4 patients underwent longitudinal follow-up for up to 5 years. Recurrent heterozygous PLAAT4 (phospholipase A and acyltransferase 4) variants (p.I14T and p.A96V) were associated with a novel autosomal dominant leukoencephalopathy, named SPDMLS. Age at onset was 11 to 51 years (median [IQR], 22 [15-29] years), with patients predominantly developing spastic paraplegia. Symbol Digit Modalities Test scores ranged from 11 to 70 in 6 available patients. Magnetic resonance imaging (MRI) demonstrated slow progression with heterogeneous brain WMH and a stereotyped pattern of symmetric, long-segment "girdle-like" spinal cord WMH accompanied by atrophy. Somatosensory- and motor-evoked potentials indicated dysfunction of the dorsal columns and corticospinal tracts, respectively. In presymptomatic carriers, spinal cord signal alterations preceded brain involvement. An oligodendrocyte-specific knock-in mouse model provided in vivo functional evidence supporting a role of PLAAT4 gain-of-function in driving demyelination, informing SPDMLS pathogenesis. Patient plasma lipidomics suggested accumulation of arachidonic acid-related lipids correlating with disability stage. This study found that PLAAT4 variants delineated SPDMLS, a clinically distinct leukodystrophy that should be considered in patients with unexplained spastic paraplegia and CNS WMH. Arachidonic acid-related lipids represent a candidate biomarker for disease progression.
中文摘要:脑白质病在临床和病因上高度异质,明确诊断仍然困难。不明原因的痉挛性截瘫并伴脑白质高信号(WMH)的患者可能被误诊为多发性硬化,从而接受不必要的免疫抑制治疗。旨在界定伴腿部痉挛的脊髓为主型脱髓鞘性白质营养不良(SPDMLS)的临床、影像和遗传特征。此病例系列纳入2019年7月至2025年8月中国罕见病联盟4家三级转诊医院的参与者。研究设计整合临床评估、全外显子测序(WES),以及与SPATAX-EUROSPA残疾分期相关的靶向血浆脂质组学。变异致病性通过少突胶质细胞特异性敲入小鼠模型评估。参与者为不明原因痉挛性截瘫合并中枢神经系统(CNS)WMH的患者及可获得的家庭成员,包括症状前携带者。检测方法为WES和遗传学特征分析。目标是识别疾病相关基因并刻画SPDMLS的临床、影像和遗传特征。共纳入来自11个无亲缘关系家庭的26人;4例患者接受最长5年的纵向随访。复发性PLAAT4(磷脂酶A和酰基转移酶4)杂合变异(p.I14T和p.A96V)与一种新的常染色体显性白质脑病相关,命名为SPDMLS。起病年龄11至51岁(中位数[IQR]为22[15-29]岁),患者主要发展为痉挛性截瘫。6例可评估患者的符号数字模态测验评分为11至70。磁共振成像(MRI)显示缓慢进展,脑WMH表现不均一,并呈刻板的对称长节段「腰带样」脊髓WMH伴萎缩。体感诱发电位和运动诱发电位分别提示背柱和皮质脊髓束功能障碍。在症状前携带者中,脊髓信号改变先于脑部受累。少突胶质细胞特异性敲入小鼠模型提供了体内功能证据,支持PLAAT4功能获得驱动脱髓鞘,并为SPDMLS发病机制提供线索。患者血浆脂质组学提示花生四烯酸相关脂质蓄积与残疾分期相关。PLAAT4变异定义了SPDMLS,这是一种临床特征独特的白质营养不良,在不明原因痉挛性截瘫伴CNS WMH的患者中应考虑。花生四烯酸相关脂质是疾病进展的候选生物标志物。

基础研究 (1篇)

Nature chemical biology IF 15.8 2026-10-28 PMID: 42951909
Excessive nicotinamide adenine dinucleotide (NAD+) consumption fuels neurological pathogenesis, yet the limited benefit of NAD+ supplementation hints at unresolved toxicity from its catabolism. Here, we identify ADP-ribose, a neglected NAD+ catabolite generated by poly(ADP-ribose) polymerase 1 (PARP1) and poly(ADP-ribose) glycohydrolase, as an inducer of neuronal ferroptosis through nucleotide metabolic rewiring. We discovered that extracellular ADP-ribose directly binds and inhibits the nucleoside transporter equilibrative nucleoside transporter 2 (ENT2; SLC29A2), suppressing nucleotide salvage and driving compensatory hyperactivation of de novo purine and pyrimidine biosynthesis. This metabolic rerouting engages xanthine oxidase (XO) and dihydroorotate dehydrogenase (DHODH) to unleash superoxide bursts, triggering lipid peroxidation and ferroptotic neuronal death. ADP-ribose accumulates across neurological disease models and its acute administration recapitulates ferroptotic neurodegeneration in vivo. Targeting ADP-ribose signaling through PARP1 knockdown, NUDT9-mediated hydrolysis or dual XO/DHODH inhibition rescues delayed cognitive deficits in intracerebral hemorrhage models. These findings define the ADP-ribose-ENT2 axis as a metabolic driver of neuronal ferroptosis and reveal a druggable vulnerability in disorders marked by NAD+ hyperconsumption.
中文摘要:烟酰胺腺嘌呤二核苷酸(NAD+)的过度消耗推动神经疾病发病机制,而补充NAD+获益有限,提示其分解代谢产生的毒性尚未被阐明。研究将ADP-核糖——由聚腺苷二磷酸核糖聚合酶1(PARP1)和聚ADP-核糖糖水解酶生成、此前被忽视的NAD+分解产物——鉴定为通过核苷酸代谢重编程诱导神经元铁死亡的因子。细胞外ADP-核糖可直接结合并抑制核苷转运体平衡型核苷转运体2(ENT2;SLC29A2),抑制核苷酸补救合成,并驱动嘌呤和嘧啶从头合成的代偿性过度激活。这一代谢改道动员黄嘌呤氧化酶(XO)和二氢乳清酸脱氢酶(DHODH),释放超氧化物爆发,引发脂质过氧化和铁死亡性神经元死亡。ADP-核糖在多种神经系统疾病模型中蓄积,急性给予ADP-核糖可在体内重现铁死亡性神经退行性变。通过PARP1敲低、NUDT9介导的水解或XO/DHODH双重抑制靶向ADP-核糖信号,可挽救脑出血模型中的迟发性认知缺陷。这些发现将ADP-核糖-ENT2轴定义为神经元铁死亡的代谢驱动因素,并揭示以NAD+过度消耗为特征的疾病中存在可成药的易感环节。

9神经变性疾病 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-10-29 PMID: 42956863
Neurodegenerative disorders are a leading cause of disability and mortality globally, but effective disease-modifying therapeutic strategies are still largely unavailable. Scutellarin is a flavonoid glycoside extracted from Erigeron breviscapus (Vant.) Hand-Mazz. It has been widely studied in preclinical models of neurodegenerative disorders. In this study, we performed a systematic review of preclinical animal studies. We combined comprehensive database retrieval with quantitative synthesis of eligible outcomes. The pooled results demonstrated that scutellarin significantly reduced cerebral infarct volume and improved neurological deficit scores in cerebral ischemia-reperfusion models. It also ameliorated learning and memory impairments in experimental Alzheimer's disease (AD) models. Consistent neuroprotective effects were also found in models of depression, anxiety, Parkinson's disease, etc. Mechanistic analysis indicated that scutellarin produces multi-level neuroprotective effects. It acts by reducing oxidative stress, inhibiting neuroinflammation, suppressing apoptosis, stabilizing the neurovascular unit and other neurobiological processes. This review first evaluated the preclinical efficacy of scutellarin through systematic review and meta-analysis. It then integrated cross-disease mechanisms with network pharmacology, reverse virtual screening and molecular docking to identify computationally predicted targets. Although scutellarin shows promising preclinical effects, its clinical translation faces major limitations. These limitations include low oral bioavailability, poor blood-brain barrier (BBB) penetration and insufficient data on brain exposure. Overall, scutellarin is a multi-target neuroprotective candidate. Future studies should focus on target validation, exposure-response modeling, delivery optimization and clinically relevant translational evaluation.
中文摘要:神经变性疾病是全球致残和致死的主要原因之一,但有效的疾病修饰治疗策略仍基本缺乏。灯盏花乙素是从灯盏细辛(Erigeron breviscapus (Vant.) Hand-Mazz.)中提取的黄酮苷,已在神经变性疾病的临床前模型中广泛研究。本研究对临床前动物研究进行了系统综述,将全面数据库检索与符合条件结局的定量合成相结合。合并结果显示,在脑缺血再灌注模型中,灯盏花乙素显著缩小脑梗死体积并改善神经功能缺损评分;在实验性阿尔茨海默病(AD)模型中,它减轻了学习和记忆损害。在抑郁、焦虑、帕金森病等模型中亦发现一致的神经保护作用。机制分析表明,灯盏花乙素产生多层次的神经保护效应,其作用包括降低氧化应激、抑制神经炎症、抑制凋亡、稳定神经血管单元及其他神经生物学过程。该综述通过系统综述和荟萃分析评估灯盏花乙素的临床前疗效,随后将跨疾病机制与网络药理学、反向虚拟筛选和分子对接整合,以识别计算预测的靶点。尽管灯盏花乙素显示出有前景的临床前效应,其临床转化仍面临重要限制,包括口服生物利用度低、血脑屏障(BBB)穿透差以及脑内暴露数据不足。灯盏花乙素可被视为一种多靶点神经保护候选物。未来研究应聚焦靶点验证、暴露-反应建模、递送优化和具有临床相关性的转化评价。

10神经影像 (1篇)

基础研究 (1篇)

IEEE transactions on medical imaging IF 12.4 2026-10-29 PMID: 42955763
State space model (SSM) is a powerful tool in neuroscience field to characterize the dynamic nature of brain functions by elucidating the mechanism of how brain system transits between brain states and how underlying states give rise to the observed neural activities. Although tremendous efforts have been made to lend the power of deep learning and mathematical insight of SSM in various functional neuroimaging studies, current state-of-the-art methods lack a holistic view of brain state evolution as a self-organized dynamical system where each part of the brain is functionally inter-connected. Since the topological co-activation of functional fluctuations exhibits an intrinsic geometric pattern (symmetric and positive definite, SPD) on the Riemannian manifold, the call for understanding how a selective set of functional connectivities in the brain supports diverse behavior and cognition emerge a new machine learning scenario of manifold-based SSM for largescale functional neuroimages. To that end, we propose a geometric neural network of SSM, coined GeoMind, designed to uncover evolving brain states by tracking the trajectory of functional dynamics on a high-dimensional Riemannian manifold of SPD matrices. GeoMind demonstrates promising results in identifying specific brain states on task-based functional Magnetic Resonance Imaging (fMRI) data, as well as in diseases early diagnosis for Alzheimer's disease, Parkinson's disease and Autism, by using resting-state fMRI. These results highlight the applicability of GeoMind in neuroscience research. To further evaluate generalizability of GeoMind, we applied GeoMind to electroencephalography (EEG) emotion datasets, outperforming competing methods and demonstrating scalability across neuroimaging modalities.
中文摘要:状态空间模型(SSM)在神经科学中是一种有力工具,可通过阐明大脑系统在不同脑状态间转换的机制以及潜在状态如何产生观测到的神经活动,刻画脑功能的动态特性。尽管已有大量工作将深度学习的能力与SSM的数学洞见用于各类功能神经影像研究,当前最先进方法仍缺乏把脑状态演化视为自组织动力系统的整体视角,即大脑各部分在功能上相互连接。由于功能波动的拓扑共激活在黎曼流形上呈现内在几何模式(对称正定,SPD),理解大脑中一组选择性功能连接如何支持多样行为与认知,催生了面向大规模功能神经影像的基于流形的SSM这一新机器学习场景。为此,我们提出一种SSM的几何神经网络,称为GeoMind,旨在通过追踪SPD矩阵高维黎曼流形上的功能动态轨迹来揭示演化中的脑状态。GeoMind在任务态功能磁共振成像(fMRI)数据上识别特定脑状态,以及利用静息态fMRI对阿尔茨海默病、帕金森病和孤独症进行疾病早期诊断方面显示出有希望的结果。这些结果凸显了GeoMind在神经科学研究中的适用性。为进一步评估GeoMind的泛化能力,我们将GeoMind应用于脑电图(EEG)情绪数据集,性能优于竞争方法,并展示出跨神经影像模态的可扩展性。

11战时心理创伤 (1篇)

临床研究 (1篇)

JAMA psychiatry IF 18.0 2026-10-28 PMID: 42949753
The ongoing war in Ukraine has generated an unprecedented burden of psychological trauma, frequently compounded by posttraumatic stress disorder, traumatic brain injury, severe physical injury, and the psychiatric consequences of captivity among former prisoners of war. In large military conflicts, civilian hospital systems are essential for delivering trauma-informed mental health care at scale while managing patients with complex, overlapping medical and psychiatric conditions under active conflict, with limited implementation guidance. This Special Communication describes the implementation and clinical workflow of the Unbroken Integrative Psycho-Trauma Care Model, a multidisciplinary health system approach embedded in the Lviv First Medical Union in Western Ukraine to organize trauma-informed mental health care within a wartime civilian hospital. From February 24, 2022, through December 31, 2025, the Lviv First Medical Union treated more than 15 000 individuals for war-related injuries and cared for more than 400 former prisoners of war. During this period, 7538 unique individuals received psychiatric care through the Unbroken Model, including 4165 who received trauma-focused psychotherapy. The model was implemented through proactive psychiatric rounds across medical and surgical departments, structured triage into 4 clinical pathways, stabilization-first care sequencing, and longitudinal case management integrated with neurological, surgical, and rehabilitation services. This organization of care enabled early identification of trauma-related distress, continuity between medical and psychiatric treatment, and adaptive delivery of trauma-focused psychotherapies within a high-volume conflict setting. The Unbroken Model demonstrates how trauma-informed mental health care can be delivered at scale within a civilian hospital during active conflict. Its primary innovation lies in the organization of care delivery, integrating proactive outreach, triage-driven pathways, multidisciplinary coordination, and stabilization-first sequencing into a unified, scalable framework. This approach may be applicable to conflict-affected and postconflict health systems worldwide.
中文摘要:乌克兰战争持续造成前所未有的心理创伤负担,常与创伤后应激障碍、创伤性脑损伤、严重躯体损伤以及前战俘被俘经历带来的精神科后果叠加。大规模军事冲突中,民用医院系统对于在持续冲突下大规模提供创伤知情精神卫生照护、同时管理具有复杂且相互重叠的躯体与精神科状况的患者至关重要,但实施指导有限。该特殊通讯描述Unbroken整合性心理创伤照护模式的实施与临床工作流程;该模式是嵌入乌克兰西部利沃夫第一医疗联盟的多学科卫生系统方法,用于在战时民用医院内组织创伤知情精神卫生照护。2022年2月24日至2025年12月31日,利沃夫第一医疗联盟治疗了超过15000名战争相关伤员,并照护了超过400名前战俘。该期间,7538名不同个体通过Unbroken模式接受精神科照护,其中4165人接受聚焦创伤的心理治疗。该模式通过医疗与外科科室的主动精神科查房、结构化的四类临床路径分诊、稳定化优先的照护排序,以及与神经科、外科和康复服务整合的纵向病例管理来实施。这种照护组织方式能够在高量冲突环境中早期识别创伤相关痛苦、保持医疗与精神科治疗之间的连续性,并适应性提供聚焦创伤的心理治疗。Unbroken模式表明,在持续冲突期间,民用医院内可以大规模提供创伤知情精神卫生照护。其首要创新在于照护提供方式的组织,将主动外展、分诊驱动路径、多学科协调和稳定化优先排序整合为一个统一、可扩展的框架。该方法可能适用于全球受冲突影响及冲突后卫生系统。

12感染性腹泻 (1篇)

基础研究 (1篇)

Clinical microbiology reviews IF 20.7 2026-10-28 PMID: 42949275
SUMMARYCampylobacter species, particularly Campylobacter jejuni and Campylobacter coli, are leading causes of bacterial gastroenteritis worldwide, responsible for an estimated 500 million cases of acute diarrheal illness annually. Despite their global prevalence and association with severe post-infectious sequelae such as Guillain-Barré syndrome, no licensed vaccine exists, and the growing threat of antimicrobial resistance further complicates clinical management. This review synthesizes current knowledge on the epidemiology, genomic diversity, antimicrobial resistance mechanisms, and vaccine development strategies for Campylobacter species, with emphasis on global trends and public health relevance in the United States. Through a One Health lens, we examine transmission across human, animal, and environmental reservoirs, and highlight the role of integrated genomic surveillance in tracking clonal expansion, horizontal gene transfer, and resistance dissemination. We also examine historical and current approaches to vaccine development, including whole-cell, subunit, glycoconjugate, and genomics-guided antigen discovery strategies. Challenges such as antigenic variability, phase variation, and inadequate experimental models have impeded progress, though recent genomics-informed interventions show promise in both poultry and human contexts. Continued investment in genomic surveillance, antimicrobial resistance, and rational antigen selection will be essential for developing effective vaccines and reducing the global burden of campylobacteriosis.
中文摘要:弯曲杆菌属,尤其是空肠弯曲杆菌与结肠弯曲杆菌,是全球细菌性胃肠炎的主要病因,每年估计造成5亿例急性腹泻病。尽管全球流行,且与吉兰-巴雷综合征等严重感染后遗症相关,目前仍无获批疫苗,抗菌药物耐药威胁上升又使临床管理更复杂。本综述整合弯曲杆菌属流行病学、基因组多样性、抗菌药物耐药机制与疫苗开发策略的现有认识,侧重全球趋势和美国公共卫生意义。以同一健康视角考察人、动物与环境储存库之间的传播,突出整合基因组监测在追踪克隆扩张、水平基因转移和耐药传播中的作用。综述还梳理疫苗开发的历史与当前路径,包括全菌体、亚单位、糖偶联以及基因组学引导的抗原发现策略。抗原变异、相位变异和实验模型不足等挑战延缓了进展,近期基于基因组学的干预在禽类与人类场景中显示出前景。持续投入基因组监测、抗菌药物耐药研究和合理抗原选择,对开发有效疫苗、降低全球弯曲杆菌病负担至关重要。

13心血管疾病 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 42105323
Alcohol and its relationship with cardiovascular disease (CVD) remain contentious. Several observational studies have found cardioprotective associations, while Mendelian randomization studies have found null or harmful effects of moderate drinking. Biases, including abstainer misclassification and sick-quitter effects, may obscure true associations. It is widely understood that former drinkers are often sick quitters. However, removal of former drinkers from analyses addresses bias in the abstainer group but fails to account for induced survivorship among current drinkers. This study sought to determine whether adjusting for biases altered the association between alcohol and CVD by comparing conventional models with those using (i) occasional drinkers as the reference group instead of lifetime abstainers and (ii) 'intention-to-treat' reallocation of former drinkers based on past drinking patterns. The Multi-Ethnic Study of Atherosclerosis is a prospective cohort study of 6814 participants aged 45-84 years between 2000 and 2002 without baseline CVD. A total of 6755 participants were included after excluding those with missing data. Alcohol consumption was self-reported and classified as lifetime abstainer, former, or current drinker [occasional (≤1 drink/week), light (2-7 drinks/week), moderate (8-14 drinks/week), heavy (>14 drinks/week)]. Outcomes included coronary artery calcium (CAC; 0, 1-100, 101-300, and >300) and clinical events [myocardial infarction (MI), stroke, cardiovascular mortality, composite major adverse cardiovascular events (MACEs), and heart failure]. Of 6755 participants, 20.6% were lifetime abstainers, 24.1% former drinkers, and 55.3% current drinkers. Adjusting for biases altered the observed relationship between alcohol and CVD, showing increased harm with light drinking, decreased protection with moderate drinking, and a dose-response relationship between alcohol and CAC, particularly CAC >300 in adjusted models. Protective associations between moderate drinking and MI [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.38-1.06] and cardiovascular mortality (HR: 0.81, 95% CI: 0.53-1.25) were attenuated and became non-significant. Light drinking shifted from null to increased risk for MI (HR: 1.46, 95% CI: 1.11-1.92), stroke (HR: 1.54, 95% CI: 1.17-2.03), MACE (HR: 1.33, 95% CI: 1.12-1.57), and heart failure (HR: 1.42, 95% CI: 1.10-1.84). Associations between alcohol and CVD in observational studies are sensitive to methodologic variation. Results from models correcting for abstainer/sick-quitter biases may help explain discrepant results from previous studies.
中文摘要:酒精与心血管疾病(CVD)的关系仍有争议。多项观察性研究发现心脏保护性关联,而孟德尔随机化研究未发现中度饮酒有益,甚至发现有害效应。戒酒者错分和病退者效应等偏倚可能掩盖真实关联。前饮酒者常为因病戒酒者,这一点已被广泛认识。然而,将前饮酒者从分析中剔除虽可处理戒酒者组的偏倚,却未能考虑当前饮酒者中由此产生的生存者偏倚。本研究通过比较传统模型与以下模型,探讨校正偏倚是否会改变酒精与CVD的关联:(i)以偶尔饮酒者而非终身戒酒者作为参照组;(ii)根据既往饮酒模式对前饮酒者进行意向性治疗式重新分配。多民族动脉粥样硬化研究是一项前瞻性队列研究,纳入2000至2002年6814名45-84岁且基线无CVD的参与者。排除数据缺失者后共纳入6755名参与者。酒精摄入为自我报告,分为终身戒酒者、前饮酒者或当前饮酒者[偶尔(≤1杯/周)、少量(2-7杯/周)、中度(8-14杯/周)、大量(>14杯/周)]。结局包括冠状动脉钙化(CAC;0、1-100、101-300和>300)和临床事件[心肌梗死(MI)、卒中、心血管死亡、复合主要不良心血管事件(MACE)和心力衰竭]。6755名参与者中,20.6%为终身戒酒者,24.1%为前饮酒者,55.3%为当前饮酒者。校正偏倚改变了观察到的酒精与CVD关系,显示少量饮酒危害增加、中度饮酒保护作用减弱,并在校正模型中呈现酒精与CAC的剂量反应关系,尤其CAC>300。中度饮酒与MI[风险比(HR):0.64,95%置信区间(CI):0.38-1.06]和心血管死亡(HR:0.81,95%CI:0.53-1.25)的保护性关联减弱并变得无统计学意义。少量饮酒从无关联转为MI(HR:1.46,95%CI:1.11-1.92)、卒中(HR:1.54,95%CI:1.17-2.03)、MACE(HR:1.33,95%CI:1.12-1.57)和心力衰竭(HR:1.42,95%CI:1.10-1.84)风险增加。观察性研究中酒精与CVD的关联对方法学差异敏感。校正戒酒者/病退者偏倚的模型结果可能有助于解释既往研究结果的不一致。

14运动神经元病 (1篇)

临床研究 (1篇)

Nature medicine IF 52.5 2026-10-27 PMID: 42946878
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease increasingly linked to T cell responses, although the mechanisms driving T cell activation and disease progression remain unclear. Here we used single-cell RNA and T cell receptor sequencing, longitudinal immune profiling and imaging flow cytometry to identify long-lived intrathecal clonotypes and antigen-presenting cell-T cell complexes displaying features of immunological synapse formation, consistent with intrathecal antigen presentation. Higher frequencies of CD4+ effector, CD4+ regulatory and CD8+ T cells in cerebrospinal fluid (CSF) were associated with slower disease progression, whereas increased circulating CD4+ effector and regulatory T cells were associated with faster progression. T cell clonotypes shared between blood and CSF exhibited distinct transcriptional states. Finally, frequencies of cytomegalovirus-specific T cells in CSF and anticytomegalovirus serum antibodies were correlated with faster progression and shorter survival in sporadic amyotrophic lateral sclerosis. These findings reveal compartmentalized immune dynamics, largely contrasting protective intrathecal responses with harmful systemic activation.
中文摘要:肌萎缩侧索硬化是一种致死性神经退行性疾病,与T细胞反应的关联日益受到关注,但驱动T细胞激活和疾病进展的机制仍不清楚。单细胞RNA测序、T细胞受体测序、纵向免疫谱分析和成像流式细胞术识别出长寿命的鞘内克隆型以及具有免疫突触形成特征的抗原提呈细胞-T细胞复合物,符合鞘内抗原提呈的表现。脑脊液中CD4+效应T细胞、CD4+调节性T细胞和CD8+ T细胞频率较高与疾病进展较慢相关,而循环中CD4+效应T细胞和调节性T细胞增多与进展较快相关。血液与脑脊液共享的T细胞克隆型呈现不同的转录状态。脑脊液中巨细胞病毒特异性T细胞频率及血清抗巨细胞病毒抗体与散发性肌萎缩侧索硬化进展较快和生存期较短相关。结果揭示区室化的免疫动态,主要表现为具有保护作用的鞘内反应与有害的系统性激活形成对比。

15胶质瘤 (1篇)

基础研究 (1篇)

Neuron IF 16.9 2026-10-27 PMID: 42945963
Recent studies have identified bi-directional communication between neurons and glioma tumors as a key driver of hyperexcitability and malignant progression. Although much of this work has focused on the activity of excitatory neurons, the roles of inhibitory neurons remain poorly defined. Using in vivo screening approaches in autochthonous glioma models, we found that the loss of a γ-aminobutyric acid (GABA) transporter (Slc6a1) enhanced glioma progression, promoted network hyperactivity, and influenced tonic GABA release by tumors. Mechanistically, we show that glioma tumors influence the activity of inhibitory neurons and that their subsequent stimulation suppresses tumor growth. Further screening of these phenomena identified diazepam binding inhibitor (DBI), a secreted negative allosteric modulator of GABA-A, as a link between glioma-related hyperexcitability and proliferation that functions through modulating inhibitory neuronal signaling. Collectively, our findings indicate that glioma tumors utilize multiple mechanisms to manipulate the activity of inhibitory neurons as a means to drive network hyperactivity, which ultimately facilitates malignant progression.
中文摘要:近期研究将神经元与胶质瘤之间的双向交流确定为过度兴奋和恶性进展的关键驱动因素。相关工作多聚焦于兴奋性神经元,抑制性神经元的作用仍不清楚。我们在自发胶质瘤模型中使用体内筛选方法,发现γ-氨基丁酸(GABA)转运体Slc6a1缺失会促进胶质瘤进展、增强网络过度兴奋,并影响肿瘤的紧张性GABA释放。机制上,胶质瘤会影响抑制性神经元活动,而随后刺激这些神经元可抑制肿瘤生长。进一步筛选这些现象发现,分泌型GABA-A受体负性变构调节剂地西泮结合抑制因子(DBI)通过调节抑制性神经元信号,将胶质瘤相关过度兴奋与增殖联系起来。这些发现表明胶质瘤利用多种机制操控抑制性神经元活动,以驱动网络过度兴奋,最终促进恶性进展。

16心代谢与卒中 (1篇)

临床研究 (1篇)

Cardiovascular diabetology IF 15.6 2026-10-26 PMID: 42947108
Natriuretic peptides (NPs) and copeptin are established cardiovascular biomarkers which can partly affect human metabolism. However, impact of human metabolism on their postprandial regulation in high-risk patients remains insufficiently understood. We aimed to characterize meal-induced changes in MR-proANP, NT-proBNP, and copeptin and to assess how these dynamics relate to acute cardiovascular (CV) events, type 2 diabetes (T2D) and insulin resistance (IR). Within the BeLOVE cohort, a subset of 373 participants with acute coronary syndrome, stroke or very high chronic CV risk underwent standardized study-specific mixed-meal testing approximately 3 months after the acute event or 1 month after enrollment for the chronic high-risk group. Fasting and 120-min postprandial concentrations of MR-proANP, NT-proBNP, copeptin, insulin and glucose were assessed. Structural equation models were used to evaluate direct and indirect associations of acute CV events, T2D, and IR (HOMA-IR) with fasting levels and postprandial changes, adjusted for age, sex and BMI. MR-proANP showed the most pronounced meal-induced suppression. NT-proBNP demonstrated only minor and inconsistent postprandial changes. For all peptides, fasting concentrations were the main determinant of their postprandial changes. A recent acute CV event was associated with higher fasting NP levels (MR-proANP: standardized β = 0.22 [0.09; 0.34]; NT-proBNP: β = 0.28 [0.15; 0.41]), but not substantially with their postprandial changes after accounting for their baseline levels. T2D showed no consistent association with fasting or postprandial NP responses. In contrast, higher HOMA-IR was associated with lower fasting MR-proANP (β=-0.19 [-0.30; -0.07]) and a stronger postprandial decline (β=-0.18 [-0.33; -0.04]). Similarly, higher HOMA-IR was linked to lower fasting NT-proBNP (β=-0.15 [-0.28; -0.03]) but showed no clear association to its postprandial change. Copeptin dynamics were largely independent of acute CV disease and metabolic status. In patients after a recent ACS or stroke, postprandial MR-proANP dynamics are linked to insulin resistance, rather than diabetes status. In contrast, the limited postprandial variability of NT-proBNP and the largely fasting-related changes of copeptin make these markers less suited for capturing short-term metabolic responses. Together, these findings highlight the value of postprandial phenotyping for understanding cardiometabolic regulation and support further evaluation of MR-proANP as a potential biomarker in future prospective studies with cardiovascular outcomes across subjects with and without acute CV event. The study protocol was approved by the institutional ethics committee (EA1/066/17) and registered in the German Clinical Trials Register (DRKS00016852).
中文摘要:利钠肽(NPs)和和肽素是已确立的心血管生物标志物,可部分影响人体代谢。但人体代谢如何影响高危患者的餐后调节仍认识不足。研究旨在描述MR-proANP、NT-proBNP和和肽素的餐后变化,并评估这些动态与急性心血管事件、2型糖尿病和胰岛素抵抗的关系。在BeLOVE队列中,373名急性冠脉综合征、卒中或极高慢性心血管风险参与者亚组接受了标准化研究专用混合餐试验,急性事件后约3个月或慢性高危组入组后1个月进行。检测空腹及餐后120分钟MR-proANP、NT-proBNP、和肽素、胰岛素和葡萄糖浓度。采用结构方程模型评估急性心血管事件、2型糖尿病和胰岛素抵抗(HOMA-IR)与空腹水平及餐后变化的直接和间接关联,并校正年龄、性别和BMI。MR-proANP表现出最明显的餐后抑制。NT-proBNP仅显示轻微且不一致的餐后变化。对所有肽类,空腹浓度是其餐后变化的主要决定因素。近期急性心血管事件与较高空腹NP水平相关(MR-proANP:标准化β=0.22 [0.09; 0.34];NT-proBNP:β=0.28 [0.15; 0.41]),但在考虑基线水平后与其餐后变化无实质关联。2型糖尿病与空腹或餐后NP反应无一致关联。相反,较高HOMA-IR与较低空腹MR-proANP(β=-0.19 [-0.30; -0.07])及更强餐后下降(β=-0.18 [-0.33; -0.04])相关。同样,较高HOMA-IR与较低空腹NT-proBNP(β=-0.15 [-0.28; -0.03])相关,但与其餐后变化无明确关联。和肽素动态在很大程度上独立于急性心血管疾病和代谢状态。在近期ACS或卒中后的患者中,餐后MR-proANP动态与胰岛素抵抗相关,而非糖尿病状态。相反,NT-proBNP餐后变异有限,和肽素变化主要与空腹状态相关,使这些标志物较不适合捕捉短期代谢反应。这些发现共同强调餐后表型分型对理解心代谢调节的价值,并支持未来在有无急性心血管事件的受试者中开展以心血管结局为终点前瞻性研究,进一步评估MR-proANP作为潜在生物标志物。研究方案经机构伦理委员会批准(EA1/066/17),并在德国临床试验注册(DRKS00016852)。

17神经影像与基础转化 (1篇)

临床研究 (1篇)

Biological psychiatry IF 10.3 2026-10-26 PMID: 42933780
The need for personalised approaches in neurosurgery arises from marked variations in the distribution and performance of functional networks among individual brains. Functional MRI and diffusion tractography have been widely adopted for neurosurgical planning. However, the way in which neuroimaging results are used clinically remains largely qualitative. This review explores how personalised neurosurgical mapping can move toward quantitative, patient-specific predictions by adopting techniques from the field of neuroscience. Exciting potential comes from extending our largely static measures of network organisation with metrics probing the dynamic nature of information processing in the brain. Such multidimensional approaches show promise to capture aspects of complex behaviour relevant to everyday function beyond the mainstream focus on language and motor skills. Yet, translation of advanced approaches into the clinic faces many challenges. Progress will require validated metrics capturing individually-unique patient profiles, methods for robust multimodal integration, clinically usable analytical tools, and outcomes that better capture real-life performance. By combining spatial, structural and temporal features of brain networks, neuroimaging may evolve from a 'localisation' tool into a platform for personalised neurosurgical prediction, intervention and longitudinal care.
中文摘要:个体化脑映射用于神经外科规划。神经外科对个体化方法的需求,源自不同个体大脑之间功能网络的分布与表现存在显著差异。功能MRI和扩散纤维束成像已被广泛用于神经外科规划。然而,神经影像结果在临床中的使用方式在很大程度上仍属定性。本综述探讨如何借助神经科学领域的技术,使个体化神经外科映射走向定量、患者特异的预测。通过用探测脑内信息处理动态特性的指标,扩展目前多为静态的网络组织测量,展现出值得期待的潜力。此类多维方法有望捕捉与日常功能相关的复杂行为方面,超越主流对语言和运动技能的关注。将先进方法转化为临床仍面临许多挑战。进展需要经过验证的指标来捕捉个体独特的患者特征,需要稳健的多模态整合方法、临床可用的分析工具,以及更好反映真实生活表现的结果。通过结合脑网络的空间、结构和时间特征,神经影像可能从「定位」工具演变为个体化神经外科预测、干预和纵向照护的平台。

18功能性发作 (1篇)

临床研究 (1篇)

JAMA neurology IF 23.6 2026-10-26 PMID: 42931745
Functional seizures (FS) are a common and disabling presentation in neurology clinics, but evidence-based treatments are difficult to access in Australia and in many regions globally. A brief, scalable, internet-delivered intervention could narrow this treatment gap. To compare a self-guided and a therapist-guided internet-based intervention for FS, each delivered alongside standard care, with standard care alone. This was a 3-arm, parallel, randomized clinical trial conducted between February 2022 and April 2024, with follow-up through to 12 months after randomization. The location was a specialist outpatient clinic in Melbourne, Australia. Included were adults (≥18 years) with a documented diagnosis of FS confirmed by video electroencephalogram monitoring and at least 4 seizures per month, excluding comorbid active epilepsy. Participants were randomized 1:1:1 to a self-guided internet-based intervention plus standard care, therapist-guided internet-based intervention plus standard care, or standard care alone. Re-PROGRAM is an internet-based intervention developed for FS, comprising 5 structured sessions integrating lifestyle factors, seizure management techniques, and elements of cognitive behavioral, acceptance and commitment, and dialectical behavior therapy. The primary outcome was monthly seizure frequency at 6 weeks, 6 months, and 12 months after randomization, recorded by daily prospective seizure diary, with retrospective estimates used for incomplete records. Secondary outcomes included depression, anxiety, quality of life, psychosocial functioning, and somatic symptoms. Of 220 individuals screened for eligibility, 107 (mean [SD] age 36.0 [12.4] years; 89 female [83%]) were randomized. Of these participants, 96 contributed to the full analysis set (29 self-guided, 34 therapist-guided, 33 standard care). The self-guided arm produced significantly greater overall reductions in monthly seizure frequency than standard care (rate ratio [RR], 0.35; 95% CI, 0.18-0.69; Holm-Bonferroni [HB] method P = .006), with sustained between-group effects at 6 weeks (RR, 0.37; 95% CI, 0.18-0.76; HB P = .02), 6 months (RR, 0.31; 95% CI, 0.12-0.78; HB P = .04), and 12 months (RR, 0.35; 95% CI, 0.16-0.78; HB P = .03). The self-guided arm also showed greater improvements in anxiety than standard care at all 3 time points and in depression and mental quality of life at 1 or more time points. The therapist-guided arm showed greater improvement in anxiety at 6 months, but reductions in seizure frequency did not reach statistical significance. Direct comparison between the 2 active arms showed no significant difference in seizure reduction (RR, 0.67; 95% CI, 0.33-1.36). Sensitivity analyses confirmed robustness of the primary findings. No adverse events occurred in any arm. Results of this randomized clinical trial show that in adults with FS, a self-guided internet-based intervention reduced seizure frequency and improved anxiety relative to standard care, offering a scalable option for patients unable to access specialist psychological care. Identifier: ACTRN12622000262707.
中文摘要:功能性发作(FS)是神经科门诊中常见且致残的表现,但基于证据的治疗在澳大利亚及全球许多地区难以获得。一种简短、可推广的互联网交付干预可能缩小这一治疗差距。比较自助式与治疗师引导的互联网干预用于FS,两者均在标准治疗基础上提供,并与单纯标准治疗对照。这是一项3臂平行随机临床试验,于2022年2月至2024年4月开展,随访至随机化后12个月。地点为澳大利亚墨尔本一家专科门诊。纳入标准为年龄≥18岁、经视频脑电图监测确认FS诊断且有记录、每月至少4次发作的成人,排除合并活动性癫痫。参与者按1:1:1随机分配至自助式互联网干预加标准治疗、治疗师引导互联网干预加标准治疗或单纯标准治疗。Re-PROGRAM是为FS开发的互联网干预,包含5次结构化课程,整合生活方式因素、发作管理技术以及认知行为、接纳承诺和辩证行为治疗的元素。主要结局为随机化后6周、6个月和12个月的每月发作频率,通过每日前瞻性发作日记记录,记录不完整时使用回顾性估计。次要结局包括抑郁、焦虑、生活质量、心理社会功能和躯体症状。筛查220人后,107人(平均[SD]年龄36.0[12.4]岁;女性89人[83%])被随机化。其中96人进入全分析集(自助式29人、治疗师引导34人、标准治疗33人)。自助式组每月发作频率的总体下降显著大于标准治疗(率比[RR]0.35;95%CI 0.18-0.69;Holm-Bonferroni[H B]法P=.006),组间效应在6周(RR 0.37;95%CI 0.18-0.76;HB P=.02)、6个月(RR 0.31;95%CI 0.12-0.78;HB P=.04)和12个月(RR 0.35;95%CI 0.16-0.78;HB P=.03)持续存在。自助式组在全部3个时间点的焦虑改善均大于标准治疗,并在1个或以上时间点的抑郁和精神生活质量方面有更大改善。治疗师引导组在6个月时焦虑改善更大,但发作频率下降未达到统计学显著性。两个主动干预臂直接比较显示发作减少无显著差异(RR 0.67;95%CI 0.33-1.36)。敏感性分析证实主要结果稳健。任何臂均未发生不良事件。这项随机临床试验结果显示,在FS成人中,自助式互联网干预相对于标准治疗减少了发作频率并改善了焦虑,为无法获得专科心理治疗的患者提供了一种可推广的选择。注册号:ACTRN12622000262707。

19心血管病 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-26 PMID: 42929148
Cardiovascular disease is the leading cause of morbidity and mortality in women, contributes markedly to healthcare expenditures, and is projected to increase substantially by 2050 if current trends continue. There is growing recognition of the complex role of sex as a biologic variable and its influence on cardiovascular health and disease. However, cardiovascular risk remains underrecognized and underaddressed in girls and women, particularly as it relates to female-specific exposure to sex hormones (both endogenous and exogenous), which are systemic modulators of cardiovascular biology. Moreover, girls and women uniquely experience fragmented care spanning specialties, including pediatrics, adolescent medicine, primary care, obstetrics and gynecology, maternal-fetal medicine, cardiology, endocrinology, hematology, and neurology. Consequently, there is a need for a unified life course approach that addresses the female-specific interconnectedness of hormonal, psychosocial, and cardiovascular health. To address these gaps, the American Heart Association, in collaboration with the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine, established a Female Life Stage framework to optimize the prevention and management of cardiovascular disease in girls and women. Physiologic changes in sex hormones define clinically distinct life stages (ie, perimenarche, ovarian cycling, perimenopause, postmenopause), which directly inform female-specific considerations for screening, prevention, and management of cardiovascular disease. This presidential advisory details the framework and its scientific rationale, highlights opportunities for implementation across settings, and identifies priorities for research, clinician education, patient advocacy, and policy. This framework offers a transformative opportunity to equitably improve cardiovascular health for all girls and women.
中文摘要:心血管疾病是女性发病和死亡的首位原因,显著推高医疗支出;若现有趋势延续,预计到2050年将大幅增加。性别作为生物学变量的复杂作用及其对心血管健康与疾病的影响日益受到认识。然而,女童和女性的心血管风险仍被低估和处理不足,尤其涉及女性一生中暴露于性激素(内源性和外源性)这一心血管生物学的系统性调节因素。女童和女性还独特地经历跨越儿科、青少年医学、初级保健、妇产科、母胎医学、心脏病学、内分泌学、血液学和神经病学等专科的碎片化照护。因此,需要统一的生命历程方法,处理女性在激素、心理社会和心血管健康方面的相互关联。为弥补这些缺口,美国心脏协会与美国儿科学会、美国妇产科医师学会和母胎医学学会合作,建立女性生命阶段框架,以优化女童和女性心血管疾病的预防与管理。性激素的生理变化界定临床上不同的生命阶段(即初潮前后、卵巢周期、围绝经期、绝经后),直接指导女性特有的心血管疾病筛查、预防和管理考量。本主席建议书详细说明该框架及其科学依据,强调在不同场景中实施的机会,并确定研究、临床医生教育、患者倡导和政策方面的优先事项。该框架为公平改善所有女童和女性心血管健康提供了变革性机会。

20女性心血管病 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-26 PMID: 42929102
There is growing recognition that the optimal prevention and management of cardiovascular disease in girls and women requires attention to sex-specific considerations relevant to the interconnected domains of hormonal, psychosocial, and cardiovascular health across the life course. Dysregulation in these health domains tends to co-occur and is associated with increased risk of cardiovascular disease. However, healthcare for girls and women is uniquely fragmented across clinical specialties, including pediatrics, adolescent medicine, primary care, obstetrics, maternal-fetal medicine, gynecology, cardiology, endocrinology, hematology, and neurology. Furthermore, inconsistent alignment across society guidelines contributes to missed opportunities to optimize cardiovascular health. Therefore, the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine convened a multisociety science advisory group and developed the Female Life Stage construct. This construct defines 4 distinct and clinically meaningful stages-perimenarche (S1), ovarian cycling (S2), perimenopause (S3), and postmenopause (S4)-to enable female-specific screening, prevention, and treatment considerations. In addition, this construct incorporates pregnancy as a unique modifying life event when cardiovascular risk may emerge or be unmasked (eg, adverse pregnancy outcomes). This scientific statement crosswalks major society guidelines, synthesizes the evidence, and provides consensus-based clinical guidance for each Female Life Stage and interconnected health domain (ie, hormonal, psychosocial, and cardiovascular health). We conclude with a call to action to improve clinical workflows, enhance clinician education, and address scientific and implementation gaps to improve cardiovascular health in girls and women.
中文摘要:人们日益认识到,女孩和女性心血管疾病的最佳预防与管理需要关注性别特异性因素,这些因素涉及整个生命过程中激素、心理社会与心血管健康等相互关联的领域。这些健康领域的失调往往同时出现,并与心血管疾病风险升高相关。女孩和女性的医疗照护却分散在儿科、青少年医学、初级保健、产科、母胎医学、妇科、心脏病学、内分泌学、血液学和神经病学等临床专科中。不同学会指南之间的一致性不足,也使优化心血管健康的机会被错失。为此,美国心脏协会、美国儿科学会、美国妇产科医师学会和母胎医学会召集多学会科学顾问组,提出女性生命阶段框架。该框架界定4个具有临床意义且彼此不同的阶段——月经初潮前后(S1)、卵巢周期活动(S2)、围绝经期(S3)和绝经后期(S4)——以支持女性特异性筛查、预防和治疗考量。该框架还将妊娠纳入为独特的生活事件修正因素,心血管风险可能在此阶段出现或被揭示,例如不良妊娠结局。这份科学声明对主要学会指南进行交叉对照,综合证据,并为每个女性生命阶段及相互关联的健康领域(即激素、心理社会与心血管健康)提供基于共识的临床指导。声明以行动呼吁作结,以改进临床工作流程、加强临床医生教育并弥补科学与实施方面的差距,从而改善女孩和女性的心血管健康。